1. Futures Jump as U.S.-Iran Truce Announced Stock futures jumped after news broke of an agreement between the U.S. and Iran to end their conflict in the Middle East, set to be signed on Friday, leading to the opening of the Strait of Hormuz and the free flow of oil. In pre-market trading, S&P 500 futures rose around 1.2%, with Nasdaq futures gaining more than 2%. Oil prices quickly fell, with benchmark WTI crude below $81 per barrel early this morning.
Late recovery leaves stock market flat: Despite dips early in the week, ahead of the excitement of Friday's SpaceX (SPCX +19.17%) IPO, the S&P 500 ended the week up 0.65% with the Nasdaq up 0.70%. First challenge for new Fed head: The Fed's meeting to set interest rates takes place today – the first under new chair Kevin Warsh. The CME FedWatch tool shows a 96.6% probability of no change, with a greater than 50% chance of a rate rise by the end of the year. 2. Paramount Gets the Green Light The Department of Justice announced its approval of the Paramount Skydance (PSKY 0.19%) takeover of Warner Bros. (WBD +0.45%) Friday afternoon. The deal would end a long-standing Hollywood rivalry, giving Paramount control of media outlets including CNN and HBO Max – with the latter to combine with Paramount+ to reach around 200 million subscribers. Paramount stock gained over 4% in pre-market trading, with Warner largely unchanged.
"The transaction is not likely to result in harm to competition or American consumers": The Antitrust Division has not announced requirements for any divestitures, clearing the way for a merger that's raised political concerns – Paramount CEO David Ellison's father Larry is a major donor to President Trump. "Fewer opportunities for creators, fewer jobs ..., higher costs, and less choice": An open letter signed by over 1,400 actors, directors, and filmmakers had opposed the takeover, and California's Attorney General Rob Bonta has yet to decide whether to try to block the deal. Rocket Lab (RKLB 10.91%) shares fell by 12% Friday, the first day of trading for SpaceX, with Firefly Aerospace (FLY 19.05%) down 19%, Redwire (RDW 11.76%) down 11%, and AST SpaceMobile (ASTS 15.53%) down 15%. It would be pretty easy to conclude that the moves were related to SpaceX, with Elon Musk's $2 trillion space giant pulling capital away from smaller space names.
The best advice is not to get caught up in near-term volatility, but to focus on the quality of the individual businesses.
Investors in space companies need to buckle up. These are highly valued stocks in the early stages of their growth trajectory. We shouldn't be surprised if any or all of these stocks – SpaceX included – lose half their value or more in the quarters to come, even if they turn out to be fabulously successful investments.
So it is when investing in companies attempting to boldly go where no one has ever gone before.
4. This Week's Key Earnings to Watch: KMX, ACN, and KR CarMax (KMX 0.50%) is due to release first-quarter earnings for fiscal 2027 Wednesday, following a 47% fall in non-GAAP EPS year over year (YoY) in the final quarter of 2026 – as sales remained sluggish in the competitive used car market, and management raised its cost reductions target. Accenture (ACN +1.43%) will post Q3 results Thursday, after TMF chief investment officer Andy Cross noted "the challenges the world's largest digital consulting firm is facing" – with only a 1% rise in Q2 bookings in local currencies. Accenture is recommended by both Team Hidden Gems and Team Rule Breakers. Kroger (KR +0.92%), recommended in Dividend Investor, reports Q1 Thursday. Digital sales helped the retail giant grow profit 37% YoY in its previous quarter, though management expects comparable sales growth of only 1-2% in the current year. Kroger has raised its dividend for 20 consecutive years. 5. Your Take What's a region or international market you're watching, and why?
Discuss with friends and family, or become a member to hear what your fellow Fools are saying!
This image and article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool has positions in and recommends AST SpaceMobile, Accenture Plc, CarMax, Rocket Lab, and Warner Bros. Discovery. The Motley Fool recommends Kroger and recommends the following options: long January 2028 $260 calls on Accenture Plc and short January 2028 $280 calls on Accenture Plc. The Motley Fool has a disclosure policy.
SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Roblox Corporation (NYSE: RBLX) common stock between October 30, 2025 and April 30, 2026, both dates inclusive (the “Class Period”), have until August 7, 2026 to seek appointment as lead plaintiff of the Roblox class action lawsuit. Captioned Mukherjee v. Roblox Corporation, No. 26-cv-05489 (N.D. Cal.), the Roblox class action lawsuit charges Roblox as well as certain of Roblox’ top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Roblox class action lawsuit, please provide your information here:
You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
CASE ALLEGATIONS: Roblox operates as a global video gaming and social networking company.
The Roblox class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Roblox’ bookings growth expectations and the overall anticipated impact from the age verification rollout while also minimizing risks associated with the rollout and its potential knock-on effects; (ii) Roblox misled investors when discussing tailwinds resulting from the age verification process while continuing to be “enormously bullish” on their tech rollouts as well as claiming to be able to “rely on [their] tremendous organic growth”; and (iii) Roblox relied far too heavily on viral events to drive growth and failed to communicate to investors the potential knock-on impacts of the age verification rollout, including how it could impact the platform’s ratings, engagement, and overall public perception.
On April 30, 2026, Roblox announced its 2026 first quarter results, allegedly reporting declines in revenue guidance and projected annual bookings growth, as well as reductions in communication engagement, app store ratings, and organic sign-ups as a result of the age verification rollout. On this news, the price of Roblox stock fell more than 18%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Roblox common stock during the Class Period to seek appointment as lead plaintiff in the Roblox class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Roblox class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Roblox class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Roblox class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026.
So what: If you purchased Roblox common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Roblox's organic growth potential; notably, that Roblox would see a significant slowdown in its growth rates as enrollment in the age verification rollout would quickly taper, compounding the resulting slowdown in on-platform communication, resulting in app store rating reductions and a swift reduction in organic growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
Stock splits can create a lot of excitement among investors, so even though they do nothing to change the fundamental value of the underlying company, anticipation of such financial events can sometimes result in a stock booking some solid short-term gains. However, long-term investors also get excited about stock splits, because there's usually only one condition under which they occur: The stock had already risen to a level where management felt compelled to split it.
Gains like that indicate a strong investment -- and Wall Street's latest stock-split stock has provided investors with some great returns since its initial public offering.
CrowdStrike (CRWD 1.27%) debuted on the public markets back in 2019, and if you purchased the stock on its first trading day and held on, you're up over 1,000% on your investment. That's a fantastic return in just about seven years of trading, and many investors would be thrilled with that. As a result of its share price gains, it's enacting a 4-for-1 stock split at the start of July. But is there room for more growth?
Image source: Getty Images.
CrowdStrike's cybersecurity offering is best-in-class CrowdStrike offers all sorts of cybersecurity products, starting with endpoint protection. This is the base capability of its software, and helps protect network endpoints from bad actors. On top of that, CrowdStrike offers 33 other modules, ranging from artificial intelligence (AI) agents to cloud security to threat hunting. Overall, the company believes that these markets offer a cumulative $149 billion market opportunity.
Today's Change
(
-1.27
%) $
-8.80
Current Price
$
682.73
But that's just the start. Generative AI isn't just being used by businesses to improve efficiency; it's also being used to identify and exploit vulnerabilities, making top-notch cybersecurity software a must-have for all businesses. As a result, the cybersecurity market is expected to rapidly expand over the next few years, leading to a $325 billion market opportunity by 2030. That leaves plenty of room for CrowdStrike to expand, which it is doing a great job of right now.
CrowdStrike likes to focus on its annual recurring revenue figure over its total revenue because that paints a better picture of how its subscription business is expanding. In the first quarter, it rose 24% year over year to $5.51 billion. That's a solid growth rate, and CrowdStrike should be able to grow at a high double-digit pace for some time due to huge cybersecurity demand. This could lead to future success, but there is one more thing investors need to watch out for: profits.
CRWD Profit Margin (Quarterly) data by YCharts.
CrowdStrike's profitability over the past few years has been poor at best. A large part of that is a result of its prodigious stock-based compensation program. In Q1, it distributed over $317 million in stock-based compensation. That's about 23% of CrowdStrike's total revenue, and that has a significant impact on CrowdStrike's bottom line. It's barely profitable.
If CrowdStrike can start to increase its profitability over the next few years, then I have confidence that it's a great stock to buy right now, even before the stock split. However, if it doesn't start to turn the profitability corner, further market-crushing returns may be harder to come by.
The DOJ ApprovalWhat the Merger CreatesWhat’s Still Standing in the WayParamount Shares SpikePSKY Price Action: At the time of publication, Paramount shares are trading 2.18% higher at $10.70, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Curated marketplace connects energy professionals, developers and partners to discover, deploy and scale trusted AI agents, domain models and digital applications
HOUSTON--(BUSINESS WIRE)--Global energy technology company SLB (NYSE: SLB) today announced the launch of the SLB Digital Marketplace, a curated digital destination designed to help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments.
The SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel. All marketplace offerings are certified against SLB standards for security, interoperability and compatibility before listing.
The launch comes as the industry moves toward agentic AI — where software can reason, act and automate across complex technical workflows. As these capabilities proliferate, energy companies will need access to a broader ecosystem of specialized tools that work together across planning, operations, data and AI.
“AI in energy is shifting from promise to performance,” said Olivier Le Peuch, chief executive officer of SLB. “The SLB Digital Marketplace is designed to accelerate that shift by creating an open ecosystem where innovation can scale, solutions can interoperate and customers can move faster from insight to action. This is how we translate AI into real performance across the energy system.”
“No single company can build every agent, model or application the energy industry will need,” said Rakesh Jaggi, president of SLB’s digital business. “The SLB Digital Marketplace is the next expression of our commitment to openness, giving energy professionals more choice while maintaining the governance and quality standards required for enterprise operations.”
The marketplace includes approximately 200 digital products including existing Ocean™ store solutions and new solutions from SLB and over 30 partners. These products span Delfi™ and Lumi™ SaaS applications, plug-ins, workflow extensions, data connectors, and Tela AI skills, agents and foundation models.
For energy professionals, the marketplace provides a single destination to evaluate and access trusted digital capabilities that extend workflows across the Delfi and Lumi environments. For developers, partners and ISVs, it provides a structured path to publish and scale solutions across the SLB ecosystem.
Developers and ISVs interested in listing applications can apply through the SLB partner program at marketplace.digital.slb.com and access additional developer resources at developer.slb.com.
Key Points:
SLB has launched the SLB Digital Marketplace, a curated destination to help energy companies rapidly discover and deploy AI and digital solutions within existing digital environments. The marketplace extends SLB’s open platform strategy, enabling SLB, partners, ISVs, developers and customers to deliver offerings through a single, governed channel certified for security, interoperability and compatibility. The launch addresses the industry shift toward agentic AI, where software can reason, act and automate across complex technical workflows. The marketplace includes approximately 200 digital products including existing Ocean™ store solutions and new solutions from SLB and over 30 partners. These products span Delfi™ and Lumi™ SaaS applications, plug-ins, workflow extensions, data connectors, and Tela AI skills, agents and foundation models. About SLB
SLB (NYSE: SLB) is a global technology company that has driven energy innovation for 100 years. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.
This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “can,” “estimate,” “intend,” “anticipate,” “will,” “potential,” “projected" and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, SLB’s new technologies and partnerships; statements about goals, plans and projections with respect to sustainability and environmental matters; forecasts or expectations regarding energy transition and global climate change; and improvements in operating procedures and technology. These statements are subject to risks and uncertainties, including, but not limited to, the inability to achieve net-negative carbon emissions goals; the inability to recognize intended benefits of SLB’s strategies, initiatives or partnerships; legislative and regulatory initiatives addressing environmental concerns, including initiatives addressing the impact of global climate change; the timing or receipt of regulatory approvals and permits; and other risks and uncertainties detailed in SLB’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.
Corning GLW said it signed a multibillion-dollar, multidecade agreement with Amazon AMZN to expand domestic production of fiber-optic products used in data centers, according to a Sunday company update.
The deal is aimed at supporting growing infrastructure needs tied to artificial intelligence workloads, which require faster data transmission and higher network capacity inside large-scale data centers. Corning said the investment will increase U.S. manufacturing capacity for optical connectivity products.
The project is expected to create about 1,000 new jobs in North Carolina, in addition to construction-related employment and workforce training initiatives. Corning said the expansion will strengthen its domestic supply chain while helping meet rising demand from cloud and AI customers.
Industry observers view the agreement as another sign that major technology companies are increasing spending on the networking and optical infrastructure needed to support next-generation AI systems. Fiber-optic technology plays a key role in connecting servers and moving large volumes of data within modern data centers.
Users can now generate Wix Harmony websites directly within Microsoft 365 Copilot without context switching
NEW YORK - Wix (Nasdaq: WIX) Wix today announced its collaboration with Microsoft to bring Wix Harmony website creation into Microsoft 365 Copilot. Anyone can now create and access Wix Harmony directly via Copilot's generally available support for the Open AI Apps SDK, meeting users where they’re already working. The integration also gives access to the entire Wix ecosystem to enable entrepreneurs and businesses to not only launch a digital presence but also manage business logic and analyze performance directly within the Microsoft 365 interface, turning a chat window into a powerful engine for growth.
Within Microsoft 365 Copilot, users can simply describe the website they want via voice or text, detailing their business, goals and brand style. Then a complete, production-ready Wix Harmony website will be generated on Wix's enterprise-grade infrastructure, with built-in capabilities for commerce, scheduling, payments, SEO and GEO, accessibility, performance, security, and more. Users can then continue the workflow in the same conversation to add relevant business capabilities, analyze performance and implement changes through natural language.
“Wix Harmony enables anyone to optimize their digital experience and turn ideas into reality,” said Shahar Talmi, GM of Developer Platform at Wix. “With this collaboration, users can now also build within Microsoft 365 Copilot, eliminating the need to jump between tools. As creation moves into chat-based interfaces, Wix Harmony ensures that building a professional website is as simple and intuitive as asking for it in the platform you’re already on.”
"Bringing the Wix Harmony website creation experience into Microsoft 365 Copilot reflects where work is headed,” said Bryan Goode, CVP of Business Applications and Agents at Microsoft. "Through an interactive, chat‑based experience, teams can design, build, and manage sites directly in the flow of their work. Our goal is to make it easy to create and move work forward while reducing toggling and context switching as much as possible.”
To begin, connect the Wix app, then simply prompt “@Wix” in the chat. The website can be accessed and managed directly from Microsoft 365 Copilot or through the Wix Business Manager. Users can manage inventory, get analytics, update product pricing, manage their bookings, and more.
The Wix app is available to Microsoft 365 Copilot users in supported markets.
About Wix.com Ltd.
Wix’s vision is to simplify complex technologies and deliver the best tools for every type of user and business to create online. Powered by advanced AI and enterprise-grade infrastructure, Wix is trusted by millions of users worldwide. Founded in 2006 and strengthened by the acquisition in 2025 of Base44, the no-code application platform, Wix is continuing to build for the future of the internet.
Wix Partners with Microsoft 365 Copilot to Bring Website Creation into the Flow of Work
Wix Partners with Microsoft 365 Copilot to Bring Website Creation into the Flow of Work Users can now generate Wix Harmony websites directly within Microsoft 365 Copilot without context sw...
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two upcoming events surrounding the BIO International Convention, taking place June 22-25, 2026, at the San Diego Convention Center in San Diego, CA.
2026 Taiwan Biotech Forum
Date: Sunday, June 21, 2026
Location: The Westin San Diego Gaslamp Quarter
Time: 1:30pm – 5:30pm PT
Sean Tucker, Ph.D., Chief Scientific Officer, will participate in a panel discussing innovative therapeutic modalities in precision medicine.
2026 BIO International Convention
Date: Tuesday, June 23, 2026
Location: San Diego Convention Center, Storytelling Stage (Booth #3035)
Time: 3:15pm – 3:35pm PT
Steve Lo, Chief Executive Officer, and Dr. Tucker will present on the innovation, development and consumer friendly approach of the company’s oral vaccine tablet platform. The discussion will highlight how targeting mucosal immunity via an oral pill could eliminate reliance on traditional needle injections and cold-chain logistics, offering a modern solution to improve global health equity and pandemic readiness.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
FINN Partners [email protected]
June 15, 2026 09:00 ET | Source: iHerb Holdings, Inc.
IRVINE, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- iHerb CEO Emun Zabihi was named an EY US Entrepreneur Of The Year® 2026 Pacific Southwest Award winner. Zabihi was selected among nearly 1,000 program participants that included 592 finalists across 17 regions competing for the title.
Since becoming CEO in 2021, Zabihi has led iHerb through a period of significant international expansion and innovation. Today, iHerb serves millions of customers worldwide through a sophisticated global eCommerce and fulfillment network built on product authenticity, transparency and customer trust. Under Zabihi's leadership, the company has strengthened its position as a global wellness eCommerce platform dedicated to helping consumers access high-quality health and wellness products wherever they live.
“This recognition is a testament to the remarkable team members who bring our mission to life every day,” said Zabihi. “As consumer demand for health and wellness continues to grow globally, we remain focused on innovation, customer trust and delivering exceptional experiences that help people live healthy lives.”
Now in its 41st year, the Entrepreneur Of The Year program honors business leaders for their ingenuity, courage and entrepreneurial spirit. It celebrates original founders who bootstrapped their business from inception or raised outside capital to grow their company, transformational CEOs who infused innovation into an existing organization to catapult its trajectory and multigenerational family business leaders who reimagined a legacy business model to strengthen it for the future.
Regional winners were chosen by an independent panel of past winners, top CEOs and business leaders. Judges assessed candidates on long-term value creation, entrepreneurial spirit, purpose-driven commitment, and significant growth and impact.
As a Pacific Southwest award winner, Zabihi will now be considered by the national judges for the Entrepreneur Of The Year 2026 National Awards, which will be presented in November at the annual Strategic Growth Forum®, where high-growth CEOs, Fortune 1000 executives and investors converge to shape the future of business.
About Entrepreneur Of The Year
Founded in 1986, Entrepreneur Of The Year® has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 60 countries and territories globally.
About iHerb, LLC
iHerb is one of the world's largest eCommerce retailers specializing in health and wellness, delivering products from approximately 2,000 brands to over 15 million active customers across 180 countries. Supported by a global workforce of nearly 2,000 team members, iHerb combines global scale with a deeply localized experience, offering service in 36 languages, over 80 currencies, and more than 40 local payment methods. iHerb's sophisticated global supply chain network spans nine climate-controlled fulfillment centers located in the U.S., Asia and the Middle East, providing customers a seamless and reliable shopping experience. Founded in 1996 and based in Irvine, California, iHerb is on a mission to make health and wellness accessible to all. For more information, please visit corporate.iherb.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68f38e01-d020-42d8-8a40-76c68932ad8c
Emun Zabihi, CEO of iHerb iHerb CEO Emun Zabihi was awarded as a 2026 EY Entrepreneur of the Year winner for the Pacific South...
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
Airlines
United Stock Surges but Airlines Are Not the Biggest Risers in the Iran Deal Rally
In this article
Airline stocks have often been the biggest movers—one way or the other—following the big moments in the Iran war. But that’s not the case on Monday.
NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA
TORONTO--(BUSINESS WIRE)--CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the CI ETFs for the month or quarter ending June 30, 2026. In all cases, the distribution will be paid on or before June 30, 2026 to unitholders of record on June 24, 2026. The ex-dividend date for all ETFs is June 24, 2026.
All CI ETFs trade on the Toronto Stock Exchange with the exception of the following, which trade on Cboe Canada: CI Canadian Equity ETF (CCDN); CI MSCI World ESG Impact Index ETF (CESG, CESG.B); CI Global Short-Term Bond Fund (ETF Series, CGSB); CI Global Healthcare Leaders ETF (CHCL.B); CI U.S. Treasury Inflation-linked Bond ETF (CTIP); CI U.S. 500 ETF (CUSA, CUSA.B); and CI U.S. 1000 ETF (CUSM.B).
ETF
Trading
Symbol
Distribution Amount
(per unit)
Payment
Frequency
CI 1-5 Year Laddered Government Strip Bond Index ETF
BXF
$0.0786
Quarterly
CI Canadian Aggregate Bond Index ETF
CAGG
$0.1290
Monthly
CI Canadian Short-Term Aggregate Bond Index ETF
CAGS
$0.1322
Monthly
CI Balanced Asset Allocation ETF
CBAL
$0.2415
Quarterly
CI Balanced+ Asset Allocation ETF Fund
CBAP
$0.0458
Quarterly
CI Galaxy Blockchain Index ETF
CBCX
$0.0000
Quarterly
CI Balanced Growth Asset Allocation ETF
CBGR
$0.2538
Quarterly
CI Balanced Income Asset Allocation ETF
CBIN
$0.3471
Quarterly
CI Digital Security Index ETF
CBUG
$0.0000
Quarterly
CI U.S. Aggregate Bond Covered Call ETF
CCBD
$0.0371
Monthly
CI Canadian Equity Index ETF
CCDN
$0.1938
Quarterly
CI Conservative Asset Allocation ETF
CCNV
$0.3028
Quarterly
CI Auspice Broad Commodity Fund (ETF Series)
CCOM
$1.0905
Quarterly
CI DoubleLine Total Return Bond US$ Fund (ETF Series)
CDLB
$0.0402
Monthly
CDLB.B
$0.0417
Monthly
CDLB.U
US$0.0417
Monthly
CI Equity+ Asset Allocation ETF Fund
CEQP
$0.0173
Quarterly
CI Equity Asset Allocation ETF
CEQT
$0.2037
Quarterly
CI MSCI World ESG Impact Index ETF
CESG
$0.2080
Quarterly
CESG.B
$0.2080
Quarterly
CI Floating Rate Income Fund (ETF Series)
CFRT
$0.0911
Monthly
CI Global Asset Allocation Private Pool (ETF Series)
CGAA
$0.0738
Monthly
CI Global Dividend Private Pool (ETF Series)
CGDI
$0.0230
Monthly
CI Global Minimum Downside Volatility Index Fund (ETF Series)
CGDV
$0.2189
Quarterly
CGDV.B
$0.2189
Quarterly
CI High Yield Bond Private Pool (ETF Series)
CGHY
$0.0228
Monthly
CGHY.U
US$0.0235
Monthly
CI Global Investment Grade ETF
CGIN
$0.0540
Monthly
CGIN.U
US$0.0540
Monthly
CI Global Quality Dividend Growth Index ETF
CGQD.B
$0.0000
Quarterly
CI Global Real Asset Private Pool (ETF Series)
CGRA
$0.0770
Monthly
CI Global Green Bond Fund (ETF Series)
CGRB
$0.0445
Monthly
CGRB.U
US$0.0461
Monthly
CI Global REIT Private Pool (ETF Series)
CGRE
$0.0860
Monthly
CI Global Sustainable Infrastructure Fund (ETF Series)
CGRN
$0.0500
Monthly
CGRN.U
US$0.0500
Monthly
CI Growth Asset Allocation ETF
CGRO
$0.2739
Quarterly
CI Global Short-Term Bond Fund (ETF Series)
CGSB
$0.0620
Monthly
CI Gold+ Giants Covered Call ETF
CGXF
$0.1417
Monthly
CGXF.U
US$0.1105
Monthly
CI Global Healthcare Leaders Index ETF
CHCL.B
$0.0000
Quarterly
CI ICBCUBS S&P China 500 Index ETF (formerly CI ICBCCS S&P China 500 Index ETF)
CHNA.B
$0.0000
Quarterly
CI Global Artificial Intelligence Fund (ETF Series)
CIAI
$0.0000
Quarterly
CI Canadian Banks Covered Call Income Class ETF
CIC
$0.0552
Monthly
CI Emerging Markets Alpha ETF
CIEM
$0.0731
Quarterly
CIEM.U
US$0.0731
Quarterly
CI Global Infrastructure Private Pool (ETF Series)
CINF
$0.0690
Monthly
CI Global Alpha Innovators ETF (formerly CI Global Alpha Innovation ETF)
CINV
$0.0000
Quarterly
CINV.U
US$0.0000
Quarterly
CI Munro Alternative Global Growth Fund (ETF Series)
CMAG
$0.0000
Quarterly
CMAG.U
US$0.0000
Quarterly
CI Marret Alternative Absolute Return Bond Fund (ETF Series)
CMAR
$0.0670
Monthly
CMAR.U
US$0.0670
Monthly
CI Alternative Diversified Opportunities Fund (ETF Series)
CMDO
$0.0640
Monthly
CMDO.U
US$0.0640
Monthly
CI Marret Alternative Enhanced Yield Fund (ETF Series)
CMEY
$0.0720
Monthly
CMEY.U
US$0.0720
Monthly
CI Money Market ETF
CMNY
$0.1002
Monthly
CI U.S. Enhanced Momentum Index ETF
CMOM
$0.0000
Quarterly
CMOM.B
$0.0000
Quarterly
CI Alternative North American Opportunities Fund (ETF Series)
CNAO
$0.0000
Quarterly
CNAO.U
US$0.0000
Quarterly
CI Alternative Investment Grade Credit Fund (ETF Series)
CRED
$0.0500
Monthly
CRED.U
US$0.0500
Monthly
CI High Interest Savings ETF
CSAV
$0.0850
Monthly
CI U.S. Treasury Inflation-Linked Bond Index ETF (CAD Hedged)
CTIP
$0.0141
Monthly
CI Target 2028 Investment Grade Bond Fund (ETF Series)
CTMA
$0.0413
Monthly
CI Target 2029 Investment Grade Bond Fund (ETF Series)
CTMB
$0.0352
Monthly
CI Target 2030 Investment Grade Bond Fund (ETF Series)
CTMC
$0.0343
Monthly
CI Global Unconstrained Bond Fund (ETF Series)
CUBD
$0.0769
Monthly
CI U.S. Minimum Downside Volatility Index ETF
CUDV
$0.0962
Quarterly
CUDV.B
$0.0962
Quarterly
CI U.S. Monthly Income Private Pool (ETF Series)
CUIG
$0.0288
Monthly
CUIG.U
US$0.0288
Monthly
CI U.S. 500 Index ETF
CUSA
$0.0000
Quarterly
CUSA.B
$0.0000
Quarterly
CI U.S. 1000 Index ETF
CUSM.B
$0.0000
Quarterly
CI Utilities Giants Covered Call ETF
CUTL
$0.0815
Monthly
CUTL.B
$0.0873
Monthly
CI U.S. Enhanced Value Index Fund (ETF Series)
CVLU
$0.1241
Quarterly
CVLU.B
$0.1241
Quarterly
CI Canadian Convertible Bond ETF
CXF
$0.0400
Monthly
CI U.S. Quality Dividend Growth Index ETF
DGR
$0.0000
Quarterly
DGR.B
$0.0000
Quarterly
DGR.U
US$0.0000
Quarterly
CI Canada Quality Dividend Growth Index ETF
DGRC
$0.0000
Quarterly
CI Europe Hedged Equity Index ETF
EHE
$0.5891
Quarterly
EHE.B
$0.5891
Quarterly
CI Emerging Markets Dividend Index ETF
EMV.B
$0.0000
Quarterly
CI Enhanced Government Bond ETF
FGO
$0.0678
Quarterly
FGO.U
US$0.0678
Quarterly
CI Health Care Giants Covered Call ETF
FHI
$0.0556
Monthly
FHI.B
$0.0655
Monthly
FHI.U
US$0.0490
Monthly
CI Investment Grade Bond ETF
FIG
$0.0320
Monthly
FIG.U
US$0.0248
Monthly
CI U.S. & Canada Lifeco Covered Call ETF
FLI
$0.0374
Monthly
CI Preferred Share ETF
FPR
$0.0768
Monthly
CI Enhanced Short Duration Bond Fund (ETF Series)
FSB
$0.0320
Monthly
FSB.U
US$0.0320
Monthly
CI Global Financial Sector ETF
FSF
$0.3026
Quarterly
CI Morningstar Canada Value Index ETF
FXM
$0.0000
Quarterly
CI International Quality Dividend Growth Index ETF
IQD
$0.0000
Quarterly
IQD.B
$0.0000
Quarterly
CI Japan Equity Index ETF
JAPN
$0.0000
Quarterly
JAPN.B
$0.0000
Quarterly
CI Energy Giants Covered Call ETF
NXF
$0.0448
Monthly
NXF.B
$0.0612
Monthly
NXF.U
US$0.0847
Monthly
CI North American Core Plus Bond ETF (formerly CI ONE North American Core Plus Bond ETF)
ONEB
$0.3451
Monthly
CI Global Core Plus Equity ETF (formerly CI ONE Global Equity ETF)
ONEQ
$0.0000
Quarterly
CI Morningstar National Bank Québec Index ETF
QXM
$0.0000
Quarterly
CI Canadian REIT ETF
RIT
$0.0675
Monthly
CI Tech Giants Covered Call ETF
TXF
$0.3779
Monthly
TXF.B
$0.4968
Monthly
TXF.U
US$0.2059
Monthly
CI U.S. MidCap Dividend Index ETF
UMI
$0.0000
Quarterly
UMI.B
$0.0000
Quarterly
CI U.S. Money Market ETF
UMNY.U
US$0.1495
Monthly
CI Morningstar International Value Index ETF
VXM
$0.0000
Quarterly
VXM.B
$0.0000
Quarterly
VXM.U
US$0.0000
Quarterly
CI Morningstar Canada Momentum Index ETF
WXM
$0.0000
Quarterly
CI Morningstar International Momentum Index ETF
ZXM
$0.6016
Quarterly
ZXM.B
$0.6016
Quarterly
Supporting Investors’ Needs
Stay in the market, minimize costs, and take advantage of a smart, simple and efficient feature designed to support investors’ needs. The CI Distribution Reinvestment Plan (DRIP) will automatically reinvest cash distributions into the CI ETF making the distribution. All of the distributions indicated in the table above will be paid in cash unless the unitholder has enrolled in the applicable DRIP of the respective ETF. For more information on how to enroll in DRIP and other considerations, please see the applicable ETF’s prospectus.
About CI Global Asset Management
CI Global Asset Management (“CI GAM”) is one of Canada’s leading investment management firms, providing a comprehensive suite of solutions – including mutual funds, exchange-traded funds and alternative investments – to help Canadians achieve their financial goals. Founded in 1965, CI GAM has built an enduring legacy of innovation, disciplined portfolio management and commitment to investor success. We partner with financial advisors, wealth management firms and institutions to serve more than 1.3 million investors. CI GAM is a subsidiary of Toronto-based CI Financial Corp., a diversified global asset and wealth management company. For more information, visit www.ci.com or follow us on LinkedIn.
Commissions, trailing commissions, management fees and expenses all may be associated with an investment in mutual funds and exchange-traded funds (ETFs). Please read the prospectus before investing. In the case of Money Market Funds, note that mutual fund securities are not covered by the Canada Deposit Insurance Corporation or by any other government deposit insurer. Important information about mutual funds and ETFs is contained in their respective prospectus. Mutual funds and ETFs are not guaranteed; their values change frequently, and past performance may not be repeated. You will usually pay brokerage fees to your dealer if you purchase or sell units of an ETF on recognized Canadian exchanges. If the units are purchased or sold on these Canadian exchanges, investors may pay more than the current net asset value when buying units of the ETF and may receive less than the current net asset value when selling them. An investor cannot invest directly in the Index. Performance of the ETF is expected to be lower than the performance of the Index.
This communication is intended for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase mutual funds managed by CI Global Asset Management and is not, and should not be construed as, investment, tax, legal or accounting advice, and should not be relied upon in that regard. Every effort has been made to ensure that the material contained in this document is accurate at the time of publication. Individuals should seek the advice of professionals, as appropriate, regarding any particular investment. Investors should consult their professional advisors prior to implementing any changes to their investment strategies. These investments may not be suitable to the circumstances of an investor.
CI Liquid Alternative investment funds have the ability to invest in asset classes or use investment strategies that are not permitted for conventional mutual funds. The specific strategies that differentiate these investment funds from conventional fund structure include increased use of derivatives for hedging and non-hedging purposes; increased ability to sell securities short; and the ability to borrow cash to use for investment purposes. While these strategies will be used in accordance with the investment funds' investment objectives and strategies, during certain market conditions they may accelerate the pace at which your investment decreases in value.
CI Global Asset Management is licensed by WisdomTree, Inc. to use certain WisdomTree indexes (the “WisdomTree Indexes”) and WisdomTree marks.
“WisdomTree®” and “Variably Hedged®” are registered trademarks of WisdomTree, Inc. and WisdomTree, Inc. has patent applications pending on the methodology and operation of its indexes. The ETFs referring to such indexes (the “WT Licensee Products”) are not sponsored, endorsed, sold, or promoted by WisdomTree, Inc., or its affiliates ("WisdomTree"). WisdomTree makes no representation or warranty, express or implied, and shall have no liability regarding the advisability, legality (including the accuracy or adequacy of descriptions and disclosures relating to the WT Licensee Products) or suitability of investing in or purchasing securities or other financial instruments or products generally, or of the WT Licensee Products in particular (including, without limitation, the failure of the WT Licensee Products to achieve their investment objectives) or regarding use of such indexes or any data included therein.
The S&P China 500 Index CAD (the “S&P Index”) underlying the CI ICBCUBS S&P China 500 Index ETF (the “S&P Licensed ETF”) managed by the Manager is proprietary to S&P Dow Jones Indices LLC (“S&P DJI”). S&P® and the names identifying the S&P Index are trademarks of Standard & Poor’s Financial Services LLC and have been licensed for use by S&P DJI and sublicensed for certain purposes by the Manager. The S&P Licensed ETF based on the S&P Index is not in any way sponsored, endorsed, sold or promoted by S&P DJI, its affiliates or licensors and those parties make no representations or warranties, express or implied, regarding the advisability of investing in securities generally or in the S&P Licensed ETF particularly or the ability of the S&P Index to track general market performance.
MSCI is a trademark of MSCI Inc. The MSCI indexes have been licensed for use for certain purposes by CI Global Asset Management (“CI GAM”) in connection with the CI ETFs (the “ETFs”). The ETF and the securities referred to herein are not sponsored, endorsed or promoted by MSCI Inc. or any of its affiliates (collectively, “MSCI”) and MSCI bears no liability with respect to any such fund or securities or any index on which such fund or securities are based. The ETF’s prospectus contains a more detailed description of the limited relationship MSCI has with CI GAM and any related funds.
Morningstar® is a registered trademark of Morningstar, Inc. (“Morningstar”) Morningstar® Canada Value IndexTM , Morningstar® National Bank Québec IndexTM, Morningstar® Canada Momentum IndexTM, Morningstar® International Value I IndexTM, and Morningstar® International Momentum IndexTM (the “Index”) are service marks of Morningstar and have been licensed for use for certain purposes by CI Global Asset Management (“CI GAM”). The securities of each of the CI Morningstar ETFs (the “ETFs”) are not in any way sponsored, endorsed, sold or promoted by Morningstar or any of its affiliates (collectively, ‘‘Morningstar’’), and Morningstar makes no representation or warranty, express or implied regarding the advisability of investing in securities generally or in the ETFs particularly or the ability of the Index to track general market performance.
Auspice Capital Advisors Ltd., DoubleLine Capital LP, One Capital Management, LLC, Galaxy Digital Capital Management LP, and Munro Partners are portfolio sub-advisors to certain funds offered and managed by CI Global Asset Management.
The CI Exchange-Traded Funds (ETFs) are managed by CI Global Asset Management, a wholly owned subsidiary of CI Financial Corp.
CI Global Asset Management is a registered business name of CI Investments Inc.
KFC's global modernization effort includes a new logo and packaging, menu upgrades, and restaurant redesigns, all aimed at improving the customer experience. KFC The Colonel is staying put. Almost everything else at KFC is changing.
The 74-year-old fried chicken chain is rolling out one of the biggest global brand overhauls in its history, betting that new sauces, specialty beverages, redesigned restaurants, and a refreshed logo and packaging can help it define what executives call the "next chapter of chicken."
The challenge is modernizing one of the world's most recognizable restaurant brands without losing the nostalgia and familiarity that made it iconic in the first place — and avoiding a rebranding catastrophe like Cracker Barrel experienced last year.
"We have a history of keeping pace with the consumer, and now everything we're doing is in service of making sure we're setting the standard for the modern chicken quick service restaurant," KFC Global CEO Scott Mezvinsky told Business Insider.
The effort comes as chicken has become one of the hottest segments in fast food. Raising Cane's, Dave's Hot Chicken, Chick-fil-A, and Popeyes have intensified competition, particularly in the US, where KFC is trying to regain momentum.
"KFC has become a global brand with an American problem, rather than an American brand with global ambitions," said Usha Haley, the Barton distinguished chair of international business at Wichita State University.
As of its latest earnings report, the chain continues to expand aggressively, with more than 34,000 restaurants across 151 countries, and it has posted sales growth almost everywhere over the last three quarters — except the US.
Though KFC has narrowed its customer-satisfaction gap with rivals over the past year, recent scores show the brand still faces pressure from newer chicken chains that have captured younger consumers' attention. The brand also remains behind Chick-fil-A, Popeyes, Raising Cane's, and Wingstop in US consumer spending, according to InMarket.
KFC's response to the competition has included revitalization efforts, such as the self-aware "Kentucky Fried Comeback" campaign, launched last year to reverse still-slumping sales in the US. Its new global strategy is built around menu upgrades, digital engagement, and what executives describe as a more immersive restaurant experience.
KFC's new line of sauces includes Chimichurri Ranch and Hot Honey Habanero, while its Kwench drink lineup features new shakes and boba drinks. KFC "The worst thing we can do is stand still — but the other thing that we can't do is just completely change who we are," Val Koropeckyj, KFC's global chief marketing officer said, adding that updating the strategy for a legacy brand with as much scale as KFC has is like maneuvering a cruise ship: "You can absolutely change course, but it takes intention and distance."
A cornerstone of that intention is a menu overhaul. KFC this year launched a new global beverage platform, called Kwench, and is pushing deeper into boneless chicken products with regional sauces like Chimichurri Ranch and Hot Honey Habanero, which executives say better align with what consumers crave.
"Our brand was built around buckets of chicken," Koropeckyj said. "That's not how people eat today."
Instead, she pointed to trends like snacking, grazing, flavor exploration, and beverages as growth opportunities.
KFC's beverage push in particular puts it squarely in the middle of a growing battle for younger consumers. Across the restaurant industry, chains from Starbucks to McDonald's have invested heavily in customizable, visually striking drinks as Gen Z and younger millennials increasingly treat beverages as affordable indulgences and social-media-friendly experiences.
The chicken chain's new global beverage platform includes boba refreshers, sparkling lemonades, iced coffees, and shakes designed to give customers new ways to treat themselves beyond mealtimes.
"People drink more and more often than they eat," Christophe Poirier, KFC's global chief concept officer, told Business Insider, adding that KFC executives see beverages as a way to attract younger consumers and create reasons to visit the brand beyond a traditional chicken meal. "We need to be in constant evolution to be forever young," Poirier said.
That evolution extends beyond the menu.
KFC's redesigned restaurants drew inspiration from the Sphere's screen in Las Vegas and the sleek design of the Apple Store. KFC Poirier is leading a redesign effort intended to transform KFC from a traditional quick-service restaurant into what he calls a "QXR" — a quality experience restaurant.
He cited Las Vegas' Sphere as an example of the kind of immersive environment consumers increasingly expect, and pointed to Apple Stores as inspiration for reducing friction between customers and employees.
His thinking is rooted in the belief that restaurants no longer compete only with other restaurants.
"The enemy in any place is what I'm calling the feed," Poirier said, referring to social media. "The new generation, they have no patience for boredom."
Future KFC locations will feature more dynamic digital elements, flexible spaces, and redesigned service areas intended to feel less transactional and more experiential — think immersive screens, layouts that shift with different dayparts, and hospitality-focused service areas that blur the line between employee and customer.
The goal, Poirier said, is to create restaurants that can "beat the feed."
Whether customers view the changes as innovation or catch-up remains an open question. Haley, the international business professor at Wichita State University, described the strategy as "optimization" rather than true reinvention.
"Nearly every element of KFC's strategy follows a path a faster rival already went down," Haley said. "Everything here makes KFC a better-running version of what it already is."
Michael Della Penna, chief strategy officer at InMarket, pointed to KFC's recent sales gains and growing digital engagement as signs that the chain's efforts are beginning to resonate, though there's still a long road ahead.
Still, Haley argues that KFC's greatest advantage isn't its sauces, beverages, or loyalty program, which will also be getting a facelift.
"KFC's heritage is a moat that rivals are spending fortunes to manufacture," she said. "The solution lies in modernizing the system, and sanctifying the icons."
That may be why, amid all the boba-inspired drinks, new sauces, and immersive restaurants, KFC isn't messing with the one asset its competitors can't copy: the older man in a white suit who has been the figurehead behind the brand's chicken for nearly three-quarters of a century.
As competitors continue to crowd into the chicken market, Mezvinsky is betting that KFC's history remains one of its biggest advantages.
"We know that chicken is the category growing the fastest," he said. "And we also know that we're the chicken kings."
Read next
Katherine Tangalakis-Lippert is a senior reporter on Business Insider's West Coast team. When she's not writing about trending business and tech news, from the latest supply chain snarls or advancements in AI, she covers the food and restaurant industries, specifically companies such as Starbucks and McDonald's.Some of her prior areas of focus have included coverage of the Supreme Court and emerging technologies such as quantum computing.Katherine has worked on award-nominated projects and has appeared on Good Morning America, NBC, CNN, and other outlets to discuss her reporting.Prior to joining Business Insider, she covered retail, hospitality, and nonprofits at the San Fernando Valley Business Journal and received a master's degree in investigative reporting from the University of Southern California.Reach outDo you have feedback or a story tip? Contact Katherine on Signal at byktl.50, or email her at [email protected] her on Twitter and Instagram @scrawlgirl.Some of her recent scoops, exclusives, and original stories include: Starbucks set up a new office. It's a 5-minute drive from the CEO's California home.Inside Starbucks' crackdown on cup notesEndless Shrimp was Red Lobster's rock bottom. Now it's clawing back.Chipotle's new PAC signals a change in how the company engages in politicsKFC lost its footing in the Chicken Wars. Now it's gunning for a 'Kentucky Fried Comeback.'A few other highlights include: Clarence Thomas raised him 'as a son.' Now he's facing 25-plus years on weapons and drug charges.Call her Ivanka Kushner'Maybe I'll just resign:' Federal workers react to DOGE productivity emailSpaceX launches cause late-night booms that rattle windows, set off car alarms, and may damage property. Locals are pushing back.The US-China tech race is moving from chips to the raw materials they're made of
To win over today's diners, KFC is prioritizing boneless chicken menu items, expanding its sauce options and designing its restaurants to keep customers' attention.
These days, the Yum Brands unit is facing stiff competition, both from upstart chicken chains and legacy giants like McDonald's that are betting big on the growing global popularity of chicken. While KFC claims to have invented the chicken quick-service restaurant category, being the first isn't the same as being No. 1, particularly in the U.S., where its sales have slumped in recent years.
"In an increasingly crowded category, we have a clear opportunity to set the standard for modern chicken in QSR," KFC Global CEO Scott Mezvinsky said Monday in a statement announcing the chain's "next chapter."
Tenders and drinksA focal point of the strategy is what KFC calls a "bold menu revamp."
As part of that, the chain plans to expand its boneless chicken options and improve its recipe for its existing tenders.
"We are moving from chicken-on-the bone to more and more boneless chicken," KFC Chief Concept Officer Christophe Poirier told CNBC.
"We are evolving our tenders to make sure that, nonnegotiable, we're going to have the biggest, the juiciest and the crispiest," he added.
KFC is also expanding its available sauces to appeal to consumers who like dunking, drenching or drizzling their chicken tenders. The chain's "global sauce pantry" has more than 20 varieties that often mix classic sauces with new flavors, like its chimichurri ranch. (KFC's tender- and sauce-centric spinoff restaurant chain Saucy, meanwhile, has grown to nearly a dozen locations, all in Florida.)
This month, restaurants in the United Kingdom and Ireland will begin rolling out the new tenders, as well as nine new sauces. Australia and the United States will follow later this summer, with more global markets expected throughout the rest of the year.
KFC is also launching a menu line called "Dunked," which features tenders, wings and sandwiches drenched in sauce. The menu items are already available in South Africa and India.
Like many fast-food restaurants, KFC is also expanding its range of drink options to include boba refreshers, sparkling lemonades and iced coffees under a new sub-brand called Kwench by KFC. Select Irish and British restaurants already sell Kwench drinks, but Australia and Canada will add them to their permanent menus this year.
"We can rapidly cascade a lot of initiatives that we're leading from the center," Poirier said, crediting the chain's nimble supply chain.
The chain's own restaurants will also look different as it rolls out new store designs. This summer, an "open-concept" restaurant in McKinney, Texas, will open its doors; an "immersive," two-story location in Dubai, United Arab Emirates, will follow in September.
Poirier compared the experience of visiting its upcoming "immersive" restaurant to seeing a concert at the Sphere in Las Vegas. KFC designed the store to distract diners from their phones and keep them engaged with the in-person experience.
Fresh branding is also part of the strategy. The chain's new logo features its Colonel Sanders mascot bookended on either side with "KFC," resembling the shape of its famous chicken buckets. KFC said the bucket will be "refreshed," while Sanders will receive a "subtle evolution," according to the chain.
ChallengesWith more than 34,000 locations worldwide, KFC is one of the largest global restaurant chains. It is also an important part of Yum's portfolio, particularly as its parent company seeks a sale of its struggling sister chain Pizza Hut.
But KFC has its own challenges.
In the U.S., the chain has been ceding share for years to newcomers like Raising Cane's. In 2021, KFC held 16% of the U.S. market share for chicken quick-service restaurants, putting it in second place behind Chick-fil-A, according to Barclays. By 2024, its market share had slipped to 9.4%, and Popeyes and Raising Cane's had leapfrogged KFC, dragging the chain down to the fourth spot.
Outside the U.S., KFC has been more successful. Yum considers KFC International to be one of its two "growth engines," along with top performer Taco Bell.
In its latest quarter, KFC reported same-store sales growth of 2%. Yum no longer shares the same-store sales of the chain's domestic business, implying that the segment is now considered immaterial to the company's broader results. China and Europe are KFC's two largest regions by system sales, with the U.S. in third place.
To revive its flagging U.S. business, Yum tapped Catherine Tan-Gillespie as KFC's new U.S. president more than a year ago. So far, her turnaround efforts have involved offering more value meals and bringing back Colonel Sanders.
KFC U.S. has seen same-store sales growth in its last three quarters, Tan-Gillespie told trade publication Restaurant Business earlier this month.
MAR002 demonstrates deep and durable IGF-1 suppression up to 64% with favorable PK properties potentially enabling once every two-week dosing
Phase 2/3 study of MAR002 in acromegaly to initiate in mid-2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today highlighted the presentation of data from its first-in-human Phase 1 study of MAR002 at the 2026 Annual Meeting of the Endocrine Society (ENDO). MAR002 is a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR).
Data from the Phase 1 study support a potential best-in-disease profile of MAR002 across safety, tolerability, pharmacodynamic effect, and dosing convenience - with deep, durable IGF-1 suppression that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care.
“The Phase 1 data presented at ENDO provide compelling proof-of-mechanism for MAR002 and strengthen our confidence as we advance into a Phase 2/3 study in patients with acromegaly expected to begin in the coming weeks,” said Rebecca Juliano, Ph.D., chief development officer of Marea Therapeutics. “MAR002 demonstrated deep and durable suppression of IGF-1, a validated biomarker and regulatory endpoint in acromegaly, while exhibiting pharmacokinetic properties that may support convenient dosing as infrequently as every two weeks. By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of patients and establish a new standard of care in acromegaly.”
“Acromegaly remains a disorder of significant unmet need, with fewer than 35% of patients achieving optimal disease control on first-line medical therapy,” said Shlomo Melmed M.D., Distinguished Professor and Dean at Cedars-Sinai. “The depth of initial IGF-1 suppression reported with MAR002 of up to 64% is particularly notable, as it appears to exceed levels seen with previously reported therapies in acromegaly. Based on these early findings, and if proven safe, MAR002 has the potential to become a significant advancement in both efficacy and treatment convenience for patients with acromegaly.”
Presentation Highlights
The first-in-human, randomized, blinded, parallel-group, placebo-controlled Phase 1 study enrolled healthy adult male volunteers and single ascending doses of MAR002 demonstrated a favorable safety and tolerability profile, with no serious adverse events or dose-limiting toxicities. Treatment with MAR002 resulted in robust and durable dose-dependent reductions in circulating insulin-like growth factor-1 (IGF-1) with up to 64% peak suppression. Favorable pharmacokinetic (PK) profile support bi-weekly to monthly dosing. About Acromegaly
Acromegaly is a rare, chronic, progressive endocrine disorder caused by prolonged exposure to excess growth hormone (GH), most commonly due to a GH-secreting pituitary adenoma, resulting in elevated insulin-like growth factor-1 (IGF-1). It leads to the abnormal enlargement of the hands, feet, and facial features, and if left untreated, can result in severe systemic complications. GH receptor antagonists (GHRA) offer therapeutic advantages in acromegaly by directly blocking GH signaling, lowering IGF-1, and improving insulin sensitivity. However, the only approved GHRA, pegvisomant, requires daily administration, resulting in suboptimal patient adherence and reduced real-world efficacy.
About MAR002
MAR002 is a potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. The in vivo PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly.
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead therapy, MAR001, is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
Toyota’s (NYSE:TM | TM Price Prediction) American depositary receipts have taken a beating in 2026, sliding 18.27% year to date as U.S. tariffs gut North American profitability and global volumes soften. Yet the setup remains compelling.
The stock trades at $174.95, and the 24/7 Wall St. price target points to $240.94 over the next 12 months. That signals meaningful upside for the world’s largest automaker, and the model rates shares a buy with high conviction.
24/7 Wall St. Price Target Summary Metric Value Current Price $174.95 24/7 Wall St. Price Target $240.94 Upside 37.72% Recommendation BUY Confidence Level 90% A Tariff-Driven Reset Has Created an Entry Point Toyota shares peaked at $245.51 in February 2026 and have unwound to current levels, leaving the stock down 6.39% over the past month and 2.43% over the past year.
The pullback stems from a brutal FY2026 result reported on May 8, 2026: full-year revenue of $323.62B, operating income down 21.5% to $24.05B, and a $8.81B direct hit from U.S. tariffs. North America swung to a $1.23B operating loss.
Global vehicle sales fell 3.1% year over year in April, Middle East exports collapsed 91.7%, and SoftBank surpassed Toyota as Japan’s largest company by market cap for the first time in 20 years. Weekly RSI sits at 33.35, an oversold reading that historically marks reversal zones.
The Case for $262 and Higher The bull-case scenario lands at $262.41, a 49.99% return. Electrified vehicles account for 48.1% of retail sales, BEV volume jumped 68.4% to 243K units in FY26, and Toyota guides FY27 BEV sales to 598K units, up 146.1%.
The Arene software platform, AREA35 production initiative, and a value-chain push targeting JPY 2.1T by 2030 build a credible 20% ROE roadmap.
Analyst targets back this optimism. Freedom Capital upgraded Toyota to Buy with a $230 target, citing hybrid demand approaching 5M units. The consensus 12-month target of $256.52 reflects 2 Strong Buy, 1 Buy, and 1 Hold rating. A $23.35B Toyota Industries take-private settled in May 2026 tightens governance and removes a long-standing cross-holding overhang.
The Risks Worth Watching The bear scenario pencils to $212.42, a positive return but well shy of the base case. FY27 guidance calls for operating income to fall 20.3% to roughly $19.16B, including a 400B yen incremental tariff and Middle East drag. BYD’s chairman has publicly targeted overtaking Toyota within five years, and China profitability remains under pressure.
Bulls argue the FY27 guide bakes in conservative 150 yen/USD FX and front-loads tariff risk. Operating cash flow of $34.94B and an $80.83B cash pile leave room to absorb the cycle. At a 10 P/E and 0.92 price-to-book, the downside is already priced in.
Toyota Price Prediction 2026-2030 The 24/7 Wall St. price target of $240.94 represents 37.72% upside, and I’m leaning into the buy rating with 90% confidence. The tipping factor is valuation: an oversold mega-cap trading near 9x earnings with positive free cash flow, a 3.58% dividend yield, and a credible electrification ramp.
The setup looks favorable on a 12 to 18 month horizon. I’d stay on the sidelines if you expect U.S. tariffs to escalate further or if FY27 guidance gets cut at the half-year mark.
Looking ahead, here is where our model projects Toyota could trade, assuming current growth trajectories and tariff conditions normalize.
Year 24/7 Wall St. Price Target 2026 $240.94 2027 $300.92 2028 $351.27 2029 $394.12 2030 $429.30 These projections assume Toyota executes on its hybrid and BEV roadmap and that U.S. tariff pressure eases by FY28. Material upside or downside could come from a BYD-driven share shift, a sharper yen reversal, or breakthrough adoption of the Arene software stack.
A Cinematic Sponsored Documentary Marking Nearly 70 Years of Toyota in America To Air on Discovery Turbo and Discovery Go
, /PRNewswire/ -- Seven decades. In the life of a nation, it's a chapter. In the life of an industry, it's an evolution. But for one company, it has been a promise kept – a promise not just to sell cars in America, but to assemble them here, alongside the people who drive them.
Built to Last: Toyota’s Mobility Journey | A Cinematic Sponsored Documentary Marking Nearly 70 Years of Toyota in America To Air on Discovery Turbo and Discovery Go As America approaches its 250th birthday, the question isn't just how far we've come. It's where we're headed next. Who assembles the vehicles that keep America moving? And how is one of the world's largest automakers preparing for an electrified future while remaining deeply rooted in the communities it has called home for nearly 70 years?
Those questions are at the heart of Built to Last: Toyota's Mobility Journey — a cinematic half-hour documentary produced by Bader Media and funded by Toyota Motor North America. Hosted by Dallas-Fort Worth-based broadcaster Celena Rae, the program takes viewers behind the scenes of Toyota's decades in America — from the first Toyopet sedan in 1950's to the rolling hills of Georgetown, Kentucky, to the new battery frontiers of Liberty, North Carolina.
The story spans eleven U.S. manufacturing plants, 1,500 dealers, and nearly 50,000 American team members. It traces Toyota's nearly 70-year commitment — from assembly lines and supplier networks to cutting-edge battery production. That commitment continues today through more than $60 billion in announced U.S. investments, including the landmark $14 billion battery manufacturing facility in Liberty, North Carolina — the largest economic development project in the state's history.
Along the way, Celena Rae meets with Toyota leaders, U.S. governors and senators, and the men and women on the factory floor who bring the company's vision to life. Together, they reveal how Toyota is navigating one of the biggest transformations in automotive history through a multi-pathway approach — advancing hybrid, plug-in hybrid, battery electric, and emerging technologies to deliver practical solutions for drivers, communities, and the future of mobility.
DISTRIBUTION
Built to Last: Toyota's Mobility Journey premieres Saturday, June 27, 2026 at 7 AM (ET & PT) on Discovery Turbo, with an encore airing on July 11, 2026 and on-demand viewing on Discovery Go. The 30-minute television program also includes a 30-second branded "Did You Know?" spot marking the 40th anniversary of Toyota Motor Manufacturing Kentucky.
Premiere schedule:
National Premiere: Saturday, June 27, 2026, 7 AM (ET & PT) on Discovery Turbo with an encore airing on Saturday, July 11, 2026. Discovery Go (Streaming): https://go.discovery.com/ WHAT VIEWERS WILL LEARN
Roots & Commitment: Inside Toyota's flagship Kentucky operation in Georgetown — Toyota's largest manufacturing plant in the world, spanning nine million square feet — where 87 "Day One" team members from 1986 are still on the floor today, anchoring a new $800 million investment in electrification. Powering the Future: A first look at the $14 billion battery "mega-site" in Liberty, North Carolina — the largest economic development project in that state's history — designed to produce 30 gigawatt-hours of battery power annually for hybrid, plug-in hybrid and battery electric vehicles assembled in the United States. Toyota Across America: A coast-to-coast exploration of Toyota's American story—from Toyota's headquarters in Plano, Texas, to the engine lines of Huntsville, Alabama; the truck capital of San Antonio; Buffalo, West Virginia's hybrid transformation; and the families, workers, and communities that have shaped generations of manufacturing excellence in Princeton, Indiana. Safety, Sustainability & Spirit: A look at the "living blueprint" for sustainability at Toyota's Plano headquarters — including one of the largest corporate solar arrays in Texas and rainwater cisterns that collect as much as 400,000 gallons — and inside Toyota's Collaborative Safety Research Center in Ann Arbor, Michigan, where life-saving innovations are shared as a "gift to the industry." A Multi-Pathway Strategy: A clear-eyed look at Toyota's many electrified vehicle options across the Toyota and Lexus brands, and how a portfolio approach including hybrids, plug-in hybrids and battery electrics are meeting the needs of every type of American driver. Join us as the program follows Celena Rae's journey across the heartland — from the Lone Star State, to the rolling hills of Kentucky, to the new battery frontiers of North Carolina — through the people, the innovation, and the spirit that are truly built to last.
About Toyota
Toyota (NYSE:TM) has been a part of the cultural fabric in the U.S. for nearly 70 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands, plus our nearly 1,500 dealerships.
Toyota directly employs approximately 48,000 people in the U.S. who have contributed to the design, engineering, and assembly of more than 36 million cars and trucks at our 11 manufacturing plants. In 2025, Toyota's plant in North Carolina began to assemble automotive batteries for electrified vehicles.
To help inspire the next generation for careers in advanced manufacturing, Toyota launched its in-person tour booking platform and virtual tour experience at www.TourToyota.com allowing guests to schedule a live tour to see several of our U.S. manufacturing facilities in action or visit all plants virtually from anywhere around the globe.
For more information about Toyota, visit www.ToyotaNewsroom.com.
MEDIA CONTACTS
Toyota Motor North America
Ed Hellwig
[email protected]
Bader Media
Hena Cuevas
+1.202.503.4460
[email protected]
Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value CreationProposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI OpportunityExisting Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at ClosingInfinite Epigenetics Transaction Value of $890 million Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity Across its Core Disease States, Combining One of the Largest Private Epigenetic Datasets with a Proprietary Biological AI Platform to Provide Earlier Warning of Disease RiskPlatform Includes Revenue-Generating Diagnostics Operations with 120,000+ Epigenetic Samples Collected Since 2020Nano and Infinite Epigenetics to Host Conference Call Today at 8:30 AM ET WALTHAM, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano”) today announced it has entered into a non-binding term sheet for a proposed business combination (“combination”) with Infinite Epigenetics™ (“Infinite Epigenetics,” “Infinite”), an artificial intelligence (“AI”)-powered preventive health and diagnostics company building a proprietary biological AI platform to read, interpret, and apply epigenetic signals at scale.
Epigenetics is the science of gene expression, shaped by lifestyle, aging, stress, and environmental factors. While traditional genetics dictates the exact sequence of one's DNA, epigenetics serves as a set of switches that can turn genes "on" or "off" without altering the underlying code. Epigenetic gene expression represents approximately 80% of one’s health, while their underlying DNA code accounts for the remaining approximately 20%. Infinite Epigenetics’ proprietary biological AI foundation model is trained on the epigenome, the operating system of the body, and reads more than 1 million epigenetic signals from a single test. Every test processed by the platform delivers actionable insights for both clinicians and patients. Furthermore, these tests strengthen the model, improving its ability to detect and predict disease earlier.
Infinite Epigenetics was co-founded by Dr. Matthew Dawson, Dr. Michael Mallin, and Brad Keywell, an entrepreneur and Original Investor and Board Member of Tempus AI, Inc. Infinite Epigenetics is building a proprietary biological AI platform that leverages the technology, proprietary data and commercial operations of its subsidiaries, TruDiagnostic, its CLIA-certified laboratory founded in 2019, and Tally Health, a consumer longevity and preventative health company founded in 2021. While the Infinite Epigenetics name and platform are relatively new, they are anchored in established operating businesses with meaningful commercial traction.
David Stehlin, Chief Executive Officer of Nano Dimension, said: “Infinite Epigenetics represented the most attractive opportunity for us to enhance shareholder value. Together with our financial advisor, Houlihan Lokey, we conducted a thorough review of approximately 20 potential opportunities across multiple sectors over many months. The company checked the key boxes we were looking for: a proven technology platform with: revenue-generating operations; a large, growing addressable market; world-class customers and partners; and a strong leadership team, experienced board members, and highly accomplished investors. We believe Infinite Epigenetics has the potential to become a category-defining company at the intersection of healthcare, biological data and AI, and that the proposed business combination would create a clear and compelling path for long-term shareholder value creation.”
As we approach the culmination of Phase 3 of Nano Dimension’s strategic plan to maximize long-term shareholder value, the proposed combination would deploy Nano’s capital base, Nasdaq platform and strategic flexibility into a high-growth healthcare AI opportunity. The transaction is intended to provide Nano shareholders with exposure to a significantly larger addressable market, while providing Infinite Epigenetics with the publicly traded company platform and resources to accelerate its mission.
Robert Pons, Chairman of Nano Dimension, said: “The proposed business combination with Infinite Epigenetics represents the next major step in Nano’s strategic plan. We believe Infinite Epigenetics offers a compelling opportunity with meaningful long-term potential, and one that we are confident can deliver lasting value for our shareholders.”
Infinite is initially focused on four major chronic diseases: cardiovascular disease, Type 2 diabetes, chronic obstructive pulmonary disease (“COPD”) and metabolic dysfunction-associated steatotic liver disease (“MASLD,” formerly known as fatty liver disease). These diseases impact more than 4 billion people worldwide and chronic diseases account for more than $4 trillion in annual healthcare costs that could be reduced through earlier and more accurate diagnosis. Infinite pairs one of the largest private collections of epigenetic data with its biological AI foundation model to address these conditions at scale.
Through TruDiagnostic and Tally Health, Infinite Epigenetics has built revenue-generating commercial diagnostics operations, collected more than 120,000 epigenetic samples since 2020, and developed a proprietary DNA methylation dataset. Since TruDiagnostic’s founding, the business has generated growing revenue while expanding its testing capabilities, research relationships, and commercial applications. Infinite has also built extensive biological and technical intellectual property (“IP”) and maintains research collaborations with leading institutions, including Harvard, Yale, Duke, Stanford, and others.
Brad Keywell, Co-Founder of Infinite Epigenetics and Original Investor and Board Member of Tempus AI, said: “We believe the most valuable healthcare AI platforms will be built on proprietary biological data, leveraging AI for novel discoveries and insights. Infinite Epigenetics has the opportunity to bring that platform logic to epigenetics, one of the most powerful and dynamic data layers in medicine.”
Transaction Overview
Under the term sheet, the proposed transaction contemplates that Nano Dimension, or a successor publicly traded company, would acquire 100% of the equity interests of Infinite Epigenetics through a merger, consolidation or other transaction structure to be mutually agreed by the parties. Upon closing of the proposed transaction, if any, the combined company is expected to operate under the Infinite Epigenetics name and continue trading on the Nasdaq Capital Market under the proposed ticker symbol “IEAI.”
Existing Nano Dimension shareholders are expected to retain a meaningful minority ownership interest in the combined company based on a stated value for Nano shares that reflects a 20% premium to Nano Dimension’s estimated net cash at closing, subject to final negotiation and execution of a definitive agreement. The parties expect that the combined company will have over $400 million in cash at closing, which the parties believe will provide ample runway and financial flexibility as Infinite Epigenetics advances toward positive cash flow, without the need for additional capital raises.
Nano believes this structure provides existing shareholders with value recognition for its cash position and listing and enables them to participate in the potential upside of a high-growth healthcare AI opportunity.
Additionally, the pre-combination Nano Dimension shareholders would receive a contingent value right (“CVR”) entitling them to certain net proceeds, if any, received by a newly formed entity and liquidation trust from the disposition of certain Nano legacy assets following the closing of the combination.
The term sheet provides for a 30-day period of mutual exclusivity, during which Nano Dimension will conduct confirmatory due diligence on Infinite Epigenetics, and the parties will finalize the terms of a definitive merger agreement.
Dr. Matthew Dawson, Co-Founder and Chief Executive Officer of Infinite Epigenetics, is expected to serve as Chief Executive Officer of the combined company. The board is expected to include representatives designated by Nano, as well as key Infinite Epigenetics leaders and directors, including Brad Keywell, an entrepreneur and Original Investor and Board Member of Tempus AI; U.S. Navy Vice Admiral (Ret.) Raquel C. “Rocky” Bono, M.D., member of the Board of Directors of Humana and former Chief Executive Officer and Director of the Defense Health Agency; Dr. Matthew Dawson; Dr. Michael Mallin; and other directors to be mutually agreed upon by the parties.
Nano Dimension expects to announce additional details regarding the proposed business combination if and when a definitive agreement is executed.
No assurance can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Any transaction would be subject to the completion of satisfactory due diligence, the negotiation of a definitive agreement and related ancillary agreements, satisfaction of conditions negotiated therein, Board of Directors and shareholder approvals, regulatory approvals, and other customary conditions.
Strategic Rationale
Exact Sciences helped demonstrate that molecular diagnostics can scale in the public markets. GRAIL helped validate the potential of methylation-based testing from blood. Tempus AI helped demonstrate the power of proprietary clinical data and AI to create a new category in precision medicine. Nano believes Infinite Epigenetics represents a potential “Digital Health 3.0” platform: moving beyond traditional disease detection toward AI-enabled interpretation of biological signals that can support earlier, more proactive health insights.
Nano believes the combination creates a differentiated AI-powered diagnostics and preventive health platform with a durable, self-reinforcing competitive moat. Each test processed adds to Infinite's proprietary biological dataset, compounding its value across clinical diagnostics, consumer longevity, pharma data, and enterprise health applications over time.
Dr. Matthew Dawson, Co-Founder and Chief Executive Officer of Infinite Epigenetics, said: “Our mission is to help move healthcare from reactive to proactive by giving clinicians and individuals earlier insight into what the body is signaling, often before symptoms appear. Detecting risk sooner is how we change outcomes for the chronic diseases that affect billions of people, and epigenetics gives us a dynamic, real-time view of that biology. The proposed combination with Nano Dimension would provide the capital and strategic flexibility to bring these insights to people at scale.”
Infinite Epigenetics Leadership
Infinite Epigenetics is led by a team of healthcare, technology, and AI entrepreneurs, scientists, and operators with experience building, scaling, and exiting category-defining companies. The founding team and leadership have collectively founded more than 10 companies, participated in prior ventures representing more than $20 billion of aggregate exit value, and contributed to more than 50 peer-reviewed studies.
Investor Presentation
An investor presentation containing additional information regarding this transaction is available here.
Conference Call and Webcast
Nano Dimension and Infinite Epigenetics will host a conference call and webcast today, June 15, 2026, at 8:30 a.m. ET to discuss the proposed business combination, strategic rationale, and Infinite Epigenetics’ AI-powered preventive health and diagnostics platform.
Participants can pre-register for the conference call in order to receive dial in information via this link: https://dpregister.com/sreg/10209845/10437fe0ae2
Participants can also dial-in/connect by following the below:
Listen in via U.S. dial-in: 1-844-695-5517
Listen via international dial-in: 1-412-902-6751
Listen via Israel toll free: 1-80-9212373
Listen via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=x3sIKph8
For those unable to participate in the conference call, a replay of the webcast and investor presentation will be available on Nano Dimension’s investor relations website following the conclusion of the call.
Advisors
Paul Hastings LLP is serving as legal counsel to Nano Dimension and Houlihan Lokey is serving as Nano Dimension's financial advisor. Latham & Watkins LLP is serving as legal counsel to Infinite Epigenetics and Wells Fargo Securities is serving as financial advisor and capital markets advisor to Infinite Epigenetics.
About Nano Dimension Ltd.
Nano Dimension Ltd. (Nasdaq: NNDM) has historically delivered advanced digital manufacturing technologies serving customers across the defense, aerospace, automotive, electronics and medical device industry segments. Following a strategic review process initiated in 2025, the Company has focused on streamlining its operations, reducing cash burn, monetizing product lines and evaluating opportunities to deploy its capital base and publicly traded company platform into a more compelling long-term value creation opportunity. Nano Dimension continues to operate its remaining product lines, while the Company advances its strategic plan and evaluates the proposed business combination with Infinite Epigenetics. For more information, please visit www.nano-di.com.
About Infinite Epigenetics
Infinite Epigenetics is an AI-powered, preventive health and diagnostics company building a proprietary biological AI platform to read, interpret, and apply epigenetic signals at scale. Powered by one of the world’s largest private DNA methylation datasets and supported by a deep body of peer-reviewed research, the company partners with biotech innovators, researchers, and healthcare organizations to translate epigenetic insights into actionable diagnostic and clinical applications. Its operating portfolio includes TruDiagnostic™, a CLIA-certified laboratory and clinical epigenetic testing company, and Tally Health™, a consumer longevity and preventive health company. For more information, visit www.infiniteepigenetics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding Nano Dimension’s strategic plan, strategic alternatives review process, expectations on the timing, economics and success of the proposed business combination, beliefs regarding the future success and long-term growth opportunities of Infinite Epigenetics and the combined company, expectations for the structure of the proposed business combination, belief that deploying Nano’s capital and publicly traded company platform into a high growth healthcare and data business offers a more compelling path to long-term value creation than continuing to scale within the advanced digital manufacturing sector, and all other statements other than statements of historical fact that address activities, events or developments that Nano Dimension intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements may be characterized by terminology such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,” “plan,” “may,” “could,” “should,” “will,” “would,” “continue,” “likely,” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. Such statements are based on management’s beliefs and assumptions made based on information currently available to management. These forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company’s actual results and performance to be materially different from those expressed or implied in the forward-looking statements. Accordingly, the Company cautions shareholders that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. The forward-looking statements contained or implied in this communication are subject to other risks and uncertainties, including, but not limited to (i) the risk that Nano Dimension and Infinite Epigenetics are unable to negotiate and enter into a definitive agreement for the proposed combination; (ii) the risk that the conditions to the closing (including any necessary shareholder approvals) are not satisfied; (iii) uncertainties as to the timing of the consummation of the proposed combination and the ability of each of Nano Dimension and Infinite Epigenetics to consummate the proposed combination; (iv) effect of the announcement of the proposed combination on the ability of Nano Dimension and Infinite Epigenetics to continue to operate their respective businesses and retain and hire key personnel and to maintain favorable business relationships; (v) risks related to the failure or delay in obtaining required approvals from any governmental or regulatory entity necessary to consummate the proposed combination; (vi) changes in the exchange ratio that could cause Nano Dimension’s shareholders and Infinite Epigenetics’ stockholders to own more or less of the combined company than is currently anticipated; (vii) risks related to the market price of Nano Dimension’s shares relative to the value suggested by the term sheet; (viii) unexpected costs, charges or expenses resulting from the proposed combination; (ix) the potential for the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the definitive agreement for the proposed combination and the other agreements entered into in connection therewith; (x) the possibility that holders of CVRs may never receive any proceeds therefrom; (xi) changes in demand for Nano Dimenson’s or Infinite Epigenetics’ products and services; (xii) global market, political and economic conditions, and conditions in the countries in which Nano Dimension and Infinite Epigenetics operate; (xiii) the impact of changes in law and government regulations; (xiv) competition in the epigenetics health industry; (xv) the risk of litigation, including any proceedings that may be instituted against Nano Dimension or Infinite Epigenetics related to the proposed combination; (xvi) the impact of rapid technological change in the epigenetics health industry; and (xvii) those discussed under the heading “Risk Factors” in Nano Dimension’s annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2026, and in any subsequent filings with the SEC.
Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this communication.
Additional Information and Where to Find It
The Company has filed a preliminary proxy statement and intends to file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for an extraordinary general meeting of shareholders that will include, among other proposals, a proposal to approve on a non-binding advisory basis a resolution regarding the continuation of Nano Dimension’s strategic alternatives review process including any related transaction approved by the Board (the “Extraordinary General Meeting”). THE COMPANY’S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND THE ACCOMPANYING WHITE PROXY CARD WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION.
Shareholders may obtain the proxy statement, any amendments or supplements to the proxy statement and other documents as and when filed by the Company with the SEC without charge from the SEC’s website at www.sec.gov.
This communication also relates to a proposed combination involving Nano Dimension and Infinite Epigenetics and may be deemed to be solicitation material in respect of the proposed combination. In connection with the proposed combination, Nano Dimension intends to file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that will contain a proxy statement of Nano Dimension that will constitute a prospectus with respect to shares of Nano Dimension’s stock to be issued in the proposed combination (the “Proxy Statement/Prospectus”). Nano Dimension may also file other documents with the SEC regarding the proposed combination. This document is not a substitute for the Proxy Statement/Prospectus or any other document which Nano Dimension may file with the SEC. INVESTORS AND SECURITYHOLDERS OF NANO DIMENSION AND INFINTE EPIGENETICS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED BY NANO DIMENSION WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED COMBINATION AND RELATED MATTERS. Nano Dimension shareholders and Infinite Epigenetics stockholders will also be able to obtain free copies of the Proxy Statement/Prospectus (when available) and other documents containing important information about Nano Dimension, Infinite Epigenetics and the proposed combination that will be filed with the SEC by Nano Dimension through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Nano Dimension will also be available free of charge on Nano Dimension’s website at https://investors.nano-di.com/sec-filings-1/default.aspx or by contacting Nano Dimension’s investor relations department by email at [email protected].
Participants in the Solicitation
The Company, the President, Chief Executive Officer and Director, David Stehlin, and each of its non-employee directors (namely, Robert Pons; Phillip Borenstein; Dr. Joshua Rosensweig and Andrew Sriubas) are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of proxies from the Company’s shareholders in connection with the matters to be considered at the Extraordinary General Meeting. Information about the compensation of our non-employee Directors is set forth in the sections titled “Director Compensation” and “Director Compensation Table” in the Company’s Annual Report, at pages 54-56, and is available here. Information about the compensation of our President, Chief Executive Officer, and Director, David Stehlin, is set forth in the section titled “Executive Compensation” in the Annual Report, at pages 56-64, and is available here. Information regarding the participants’ holdings of the Company’s securities can be found in the section titled “Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters” in the Company’s Annual Report on pages 64-65 and is available here, and as updated in the filings referenced below. Supplemental information regarding the participants’ holdings of the Company’s securities can be found in SEC filings on Statements of Change in Ownership on Form 4 filed with the SEC on May 29, 2026 for Mr. Stehlin (available here) and June 12, 2026 (available here). Such filings are available on the Company’s website at https://investors.nano-di.com/sec-filings-1/default.aspx or through the SEC’s website via the links referenced above.
Updated information regarding the participants’ direct or indirect interests, by security holdings or otherwise, is be set forth in the Company’s preliminary proxy statement on Schedule 14A and will be set forth in the Company’s definitive proxy statement and other materials to be filed with the SEC in connection with the Extraordinary General Meeting.
Nano Dimension and its directors and executive officers may be deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of proxies from Nano Dimension’s shareholders in connection with the proposed combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from Nano Dimension’s shareholders in connection with the proposed combination will be set forth in the Proxy Statement/Prospectus on Form S-4 for the proposed combination, which is expected to be filed with the SEC by Nano Dimension. Investors and securityholders of Nano Dimension and Infinite Epigenetics are urged to read the Proxy Statement/Prospectus and other relevant documents that will be filed with the SEC by Nano Dimension carefully and in their entirety when they become available because they will contain important information about the proposed combination.
The Underwriting BusinessThe World Cup OpportunityRobinhood Shares SurgeHOOD Price Action: At the time of publication, Robinhood shares are trading 4.92% higher at $97.77, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
FREMONT, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced the appointment of Shanker Trivedi to its board of directors, effective immediately.
Mr. Trivedi recently retired from NVIDIA Corporation after a distinguished 17-year tenure, where he last served as senior vice president of enterprise business. During his time there, he played a key role in leading the growth of NVIDIA's data center and enterprise businesses, helping drive the company's expansion into a global leader in accelerated computing and artificial intelligence infrastructure.
"We are delighted to welcome Shanker to our board of directors," said Badri Kothandaraman, president and CEO of Enphase Energy. "Shanker brings decades of experience building global technology businesses and has driven advances in one of the most significant technology transformations of our time — the rise of AI and accelerated computing. His deep expertise in data centers, enterprise infrastructure, go-to-market strategy, and ecosystem development will be invaluable as Enphase expands its technology platform and explores new opportunities in energy management, power conversion, and AI-driven energy infrastructure."
"I am honored to join Enphase’s board of directors," said Mr. Trivedi. "Enphase has established itself as a global leader in energy technology through a relentless focus on innovation, product quality, and customer experience. As electrification, AI, and energy infrastructure increasingly converge, I believe Enphase is uniquely positioned to deliver differentiated solutions designed to help customers manage and optimize energy. I look forward to working with the board and management team as the company pursues its next phase of growth."
Mr. Trivedi brings more than 30 years of leadership experience in enterprise technology, data centers, cloud infrastructure, and go-to-market execution. At NVIDIA, Mr. Trivedi led worldwide sales for data center and professional visualization products, as well as business development for all industry verticals other than gaming, including manufacturing, healthcare, financial services, telecommunications, government, and education. Prior to NVIDIA, he held various senior leadership positions at Callidus Software, Sun Microsystems, IBM, and ICL. Mr. Trivedi earned a Master of Business Administration degree from the Indian Institute of Management Calcutta and a Master of Science degree in Mathematics and Computer Science from the Indian Institute of Technology Delhi.
About Enphase Energy, Inc.
Enphase Energy, a global energy technology company based in Fremont, CA, is the world's leading supplier of microinverter-based solar and battery systems, EV chargers, home energy management systems, and virtual power plant (VPP) solutions. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. The company revolutionized the solar industry with its microinverter-based technology and has shipped approximately 87.8 million microinverters, with more than 5.2 million Enphase-based systems deployed in over 165 countries. For more information, visit https://enphase.com/.
Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding the expected benefits of Mr. Trivedi's appointment to the board of directors, Enphase Energy's growth opportunities, technology roadmap, market expansion initiatives, and future business prospects. These forward-looking statements are based on Enphase Energy’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, product development, market demand and competitive environments, and other factors discussed in Enphase Energy's filings with the Securities and Exchange Commission, including those risks described in more detail in Enphase Energy's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, or changes in its expectations, except as required by law.
Insight Holdings Group, LLC, one of several affiliated entities within the Insight Partners family of funds -- which collectively carry a 10% owner designation for Coursera (COUR +0.19%) -- reported the indirect sale of 78,628 shares of common stock for a transaction value of approximately $447,000 on May 18, 2026, according to an SEC Form 4 filing.
Transaction summaryMetricValueShares sold78,628Shares sold (indirect)78,628Transaction value$447,000Post-transaction shares (direct)0Post-transaction shares (indirect)0Post-transaction value (direct ownership)$0Transaction value based on SEC Form 4 reported price ($5.69); post-transaction value is $0.00 as of May 18, 2026, since all shares were disposed of.
Key questionsWhat proportion of Insight Holdings Group, LLC’s Coursera position was affected by this transaction?
The sale represented 100% of the reporting entity's indirect holdings in Coursera common stock -- both its indirect position and total reported position were reduced to zero as of May 18, 2026.Did the transaction involve direct or indirect ownership, and what does this imply?
All 78,628 shares were held and sold via indirect ownership. There were no direct holdings before or after the transaction, meaning the entity's exposure was held through affiliated funds or vehicles rather than through a personal or direct account.How does the transaction value relate to Coursera’s trading price at the time?
Shares were sold at approximately $5.69 per share, resulting in a total transaction value of approximately $447,000.Company overviewMetricValueMarket cap$1.5 billionRevenue (TTM)$773.9 millionNet income (TTM)-$63.7 million1-year price change*-37.2%* 1-year price change calculated using June 12, 2026, as the reference date.
Company snapshotCoursera, Inc. is a global online learning platform -- originally launched in 2012 -- that partners with universities and industry leaders to deliver accessible education at scale. As of May 2026, Coursera completed its merger with Udemy, Inc., creating a combined platform serving approximately 290 million learners worldwide.
Offers online courses, professional certificates, degree programs, and enterprise workforce training across disciplines, including data science, business, computer science, and health.Serves individual learners, higher education institutions, and enterprise clients; generates revenue through course enrollments, certification fees, institutional partnerships, and subscription offerings.What this transaction means for investorsGiven the timing of Insight Partners’ sale, this is an interesting transaction. On the surface, seeing an Insight Partners affiliate quietly sell off its entire remaining position is the kind of thing that can make investors nervous. But this is less a vote of no-confidence and more likely a routine portfolio exit by a venture-stage investor that has been unwinding a long-held position over time.
Insight Partners is a technology-focused venture and private equity firm, and Coursera has been in its portfolio since before the company's IPO. Importantly, this filing covers only one entity within the broader Insight Partners family -- Insight Holdings Group, LLC -- which held just 78,628 shares before the sale. Other Insight-affiliated funds continue to hold tens of millions of Coursera shares, as reflected in a separate Form 4 filed the same day. So while this particular entity has fully exited its position, Insight Partners as a whole remains a substantial Coursera shareholder.
What may be more meaningful to long-term investors is what's happening at the company itself. Coursera just completed its merger with Udemy in May 2026, uniting two of the world's largest online learning platforms into a single organization serving roughly 290 million learners and 18,000 enterprise customers. The same day as this filing, Coursera's board announced a $500 million share repurchase program -- a meaningful signal of leadership's confidence in the company's balance sheet and future cash generation. On the financial front, Coursera reported Q1 2026 revenue of approximately $196 million, up 9% year over year, including its fourth consecutive quarter of double-digit growth in the Consumer segment. The company also reaffirmed its full-year 2026 revenue guidance of $805 to $815 million. The Udemy integration brings meaningful scale, though investors will want to watch how smoothly the combined business executes going forward.
For investors, the key takeaway is that this sale reflects one fund exiting a legacy position, not a broader signal that Insight Partners has lost faith in Coursera. Other Insight-affiliated entities continued to hold approximately 28.4 million Coursera shares as reported in a separate filing -- a significant remaining stake by any measure. With the Udemy merger now complete and a $500 million buyback authorized, the more interesting story is how the combined company will perform from here.
Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved >5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 years Favorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatment Patient‑reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment satisfaction, including emotional well‑being, energy levels and confidence in managing their classic congenital adrenal hyperplasia with CRENESSITY , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new Phase 3 CAHtalyst® Adult study data demonstrating improved cardiometabolic outcomes alongside sustained glucocorticoid dose reduction through up to two years of treatment with CRENESSITY® (crinecerfont) for classic congenital adrenal hyperplasia. These results, together with additional presentations highlighting improvement in bone outcomes and patient-reported quality of life survey outcomes, were presented at the Endocrine Society's annual meeting, ENDO 2026, in Chicago.
Long-term supraphysiologic glucocorticoid (GC) treatment in adults with classic congenital adrenal hyperplasia (CAH) is associated with obesity, insulin resistance, increased cardiometabolic risk and adverse effects on bone health. In these analyses, adults with classic CAH taking CRENESSITY for up to two years experienced improvements in weight, body composition and insulin resistance, key markers of long-term health, with sustained GC dose reductions and maintenance of baseline androgen control.
"These two-year results provide important evidence on the long-term impact of CRENESSITY for adults living with classic congenital adrenal hyperplasia," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "Sustained improvements across key clinical outcomes, including both cardiometabolic and bone outcomes, underscore the potential of CRENESSITY to meaningfully redefine lifelong disease management and improve health. We are excited to share these new data with the scientific community as we continue to deepen our understanding of the long-term impact of CRENESSITY on patient outcomes and quality of life."
CAHtalyst adult participants (N=182) who completed the 24-week, double-blind, placebo-controlled period and the subsequent six-month, open-label period of the study continued treatment with CRENESSITY in an ongoing open-label extension.
Sustained Improvements in Weight‑related and Metabolic Outcomes over Two Years
Cardiometabolic clinical outcomes were evaluated through up to two years of CRENESSITY treatment, including changes in body weight, body mass index (BMI), body composition and insulin resistance, as assessed by the homeostatic model assessment for insulin resistance (HOMA‑IR) at Months 12 and 24. To avoid potential confounding from glucagon-like peptide-1 (GLP-1) receptor agonists and/or glucose-dependent insulinotropic polypeptide (GIP) use, data from participants taking these medications (n=9) were excluded from the time the medication was started.
Sustained improvements were observed, with mean reductions from baseline in body weight, BMI and insulin resistance.
Among participants who were overweight or obese at baseline, more than one-third achieved clinically meaningful weight loss (>5%) at two years, with reductions in fat mass exceeding changes in lean mass. Improvements in insulin resistance were also sustained through two years, including among participants with insulin resistance at baseline, 43% of whom were no longer insulin resistant at two years. Measure
Baseline
Change
from
Baseline at
Month 12
Change from
Baseline at
Month 24
Mean daily GC dose (mg/m²/day HCe*)
17.6
-6.8
(‑37%)
-7.0
(‑38%)
Mean BMI (kg/m2)†‡
32.5
‑0.9
‑0.9
Percentage of overweight/obese participants who
achieved >5% reduction in weight†‡
—
31%
(35/114)
37%
(35/95)
Change in percent fat mass versus percent lean
mass†‡
—
‑0.9%
versus
+0.7%
‑0.9%
versus
+0.8%
Mean HOMA‑IR‡§
5.3
‑1.5
‑1.7
Percentage of participants who achieved
HOMA-IR ≤2.5‡§
—
40%
(26/65)
43%
(24/56)
*HCe denotes hydrocortisone equivalents.
†Among participants who were overweight or obese (BMI ≥25 kg/m2) at baseline. Clinically meaningful weight loss is defined as >5% reduction in body weight.
‡Data from participants who were taking a GIP/GLP-1 receptor agonist were excluded from the time the medication was started.
§Among participants with insulin resistance (HOMA-IR >2.5) at baseline.
"For many adults with classic congenital adrenal hyperplasia, long‑term supraphysiologic glucocorticoid exposure can contribute to weight gain and insulin resistance, adding to cumulative cardiometabolic burden over time," said Oksana Hamidi, D.O., M.S.C.S., Associate Professor of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center. "What makes these two-year data particularly meaningful is that they demonstrate sustained glucocorticoid reductions alongside improvements in insulin resistance and body composition, outcomes that are closely tied to future cardiometabolic risk and long-term health."
Favorable Trends Observed Across Bone-related Outcomes
Bone‑related outcomes were also assessed over two years of CRENESSITY treatment, including bone mineral density (BMD) z scores at Months 12, 18 and 24, and mean changes from baseline in bone turnover markers at Months 12 and 18.
Favorable trends were observed in mineral density measurements (lumbar spine and total hip) and bone turnover (formation/resorption).
BMD z scores trended toward incremental improvement over time, with the greatest improvement in the lumbar spine where there is the largest proportion of GC-sensitive bone. All bone turnover markers increased from baseline to Month 12, potentially reflecting recovery from suppression caused by supraphysiologic GC doses. From Month 12 to Month 18, markers of bone formation remained at similar levels, while markers of bone resorption showed a decreasing trend. Patient‑reported Survey Data Reflect Meaningful Changes in Lived Experience
To understand patient perspectives following long‑term CRENESSITY treatment, a cross‑sectional survey was conducted among adult U.S. participants (n=48) at their final open-label extension visit.
In the survey, 96% of respondents indicated they were moderately or very satisfied with their experience with CRENESSITY treatment, and a majority of participants reported:
Having more hope for their future living with classic CAH (98%). Feeling more in control of their classic CAH (94%). Being more optimistic about reducing the long-term impacts of high-dose GCs (96%) and elevated adrenocorticotropic hormone or androgens (92%). Large majorities of participants who experienced improvements also reported those changes as meaningful, including less side effects associated with high-dose steroids (93%) and less worry about weight gain associated with high-dose steroids (81%), as well as high levels of treatment satisfaction, with 98% reporting they would recommend CRENESSITY and 96% reporting they preferred treatment with CRENESSITY over treatment without CRENESSITY.
Across analyses, CRENESSITY was generally well tolerated through up to two years of treatment, with no new safety signals observed during long‑term follow‑up.
These findings build on two‑year data presented earlier this year at the American Association of Clinical Endocrinology 2026 Annual Meeting and the Pediatric Endocrine Society 2026 Annual Meeting in adults and pediatrics, respectively.
Presentations at the ENDO 2026 annual meeting included:
CAHtalyst Adult Study Two-Year Results
Title: Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst Adult Study (Oral Presentation #ORF32-07)
Authors: Oksana Hamidi, D.O., et al
Title: Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study (Poster Presentation #SUN-458)
Authors: Irina Bancos, M.D., et al
Title: A Cross-sectional Survey on Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia in the United States Participating in CAHtalyst Adult Open-Label Extension Study (Poster Presentation #SUN-467)
Authors: Sonal Vaid, M.D., et al
Title: Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in CAHtalyst Adult Study (Poster Presentation #SUN-468)
Authors: Maria Vogiatzi, M.D., et al
CAHtalyst Pediatric Study Two-Year Results
Title: Characterization of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Who Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont (Oral Presentation #ORF32-05)
Authors: Maria Vogiatzi, M.D., et al
Title: Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SAT-465)
Authors: Natalie Nokoff, M.D., et al
Title: Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SUN-465)
Authors: Kyriakie Sarafoglou, M.D., et al
Additional Presentations
Title: Long-term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry ("New Therapies and Perspectives for Congenital Adrenal Hyperplasia and Adrenal Insufficiency" Rapid Fire Presentation #ORF32-02 and Poster Presentation #MON-495)
Authors: Oksana Lekarev, D.O., et al
Title: Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11β-Hydroxylase Deficiency: A Case Series (Poster Presentation #SAT-466)
Authors: Kyriakie Sarafoglou, M.D., et al
Title: A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia (Poster Presentation #SAT-459)
Authors: Ahmed Khattab, M.D., et al
About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.
Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at supraphysiologic doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with supraphysiologic GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to cardiometabolic and fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).
About CRENESSITY® (crinecerfont)
CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.
CRENESSITY comes in capsules and an oral solution. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.
About the CAHtalyst® Studies
The Phase 3 CAHtalyst global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY® (crinecerfont) in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients.
The CAHtalyst Pediatric study included 103 pediatric patients four to 17 years of age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved.
The CAHtalyst Adult study included 182 adult patients 18 to 58 years of age. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved.
Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing.
Important Information
Approved Uses
CRENESSITY® (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
IMPORTANT SAFETY INFORMATION
Do not take CRENESSITY if you:
Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.
CRENESSITY may cause serious side effects, including:
Allergic reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.
Risk of Sudden Adrenal Insufficiency or Adrenal Crisis with Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.
Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.
The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds.
These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.
Please see full Prescribing Information.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, CRENESSITY and CAHtalyst are registered trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH, including its potential support sustained glucocorticoid dose reductions and contribute to improvements in certain cardiometabolic, bone health and patient-reported outcomes; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of CRENESSITY; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.
Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver survey data showed universal satisfaction with CRENESSITY, willingness to recommend treatment and increased optimism about their child's future quality of life following treatment initiation , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst® Pediatric study showing positive growth outcomes in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Patients with advanced bone age at baseline experienced slowed bone age progression and improved predicted adult height after two years of treatment. These data were presented at the Endocrine Society's annual meeting, ENDO 2026, in Chicago.
"Treatment decisions made during growth years can have lifelong implications for children and adolescents with classic congenital adrenal hyperplasia," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "Excess adrenal androgens can accelerate bone maturation and limit adult height. These two‑year data suggest that sustained androgen control with CRENESSITY, combined with reduced glucocorticoid exposure, may help address abnormal growth in pediatric patients by slowing the advancement of bone age and narrowing the gap between bone age and chronological age."
Pediatric participants who completed the 28‑week, double‑blind, placebo‑controlled period and the subsequent six‑month, open‑label period of the CAHtalyst Pediatric study continued treatment with CRENESSITY in an ongoing, open‑label extension.
Slowed Bone Age Progression and Improved Predicted Adult Height
In the subset of growing pediatric patients (n=41), changes in bone age and predicted adult height were evaluated at Month 24. Bone age was assessed using bone age standard deviation score (SDS), a measure that compares skeletal maturity to age- and sex-matched norms.
Among those with advanced bone age at baseline (n=24), bone age SDS remained stable or improved in most patients with up to two years of CRENESSITY treatment. Mean bone age SDS decreased by 1.12, with a subset of patients (n=9) demonstrating reductions greater than two standard deviations. In this subset of patients, mean predicted adult height increased by 4.7 cm from baseline. Together the data suggest that sustained hormonal control and substantial glucocorticoid (GC) reductions enabled by CRENESSITY may positively influence growth during childhood and adolescence.
"Accelerated bone age is one of the most challenging complications we face when managing classic congenital adrenal hyperplasia in growing children because it can permanently affect adult height," said Maria G. Vogiatzi, M.D., Division of Endocrinology at Children's Hospital of Philadelphia, Principal Investigator for the CAHtalyst Pediatric study and lead author of the growth analysis. "Seeing stabilization and even improvement in bone age over two years in a subset of patients is encouraging and suggests meaningful progress in addressing a key driver of compromised growth during the critical development years."
Caregiver-reported Survey Data Reflects Satisfaction with CRENESSITY and Increased Optimism
To further explore caregiver perspectives and patient experience following long-term treatment with CRENESSITY, a cross-sectional, caregiver-reported survey of eligible U.S. participants from the CAHtalyst Pediatric open-label extension (n=29; preliminary analysis) was conducted at patients' latest site visits.
Among caregivers in the preliminary survey analysis, 100% (29/29) reported:
Overall satisfaction with CRENESSITY. Likelihood to recommend CRENESSITY to others with classic congenital adrenal hyperplasia (CAH). Increased optimism about reducing risks of long-term impacts associated with high-dose steroid use, including 79% (23/29) who reported feeling less concern about steroid-associated weight gain. Nearly all respondents (97%, 28/29) reported greater overall hope for their child's future living with classic CAH, with 93% (27/29) indicating increased optimism about reducing long-term impact of high levels of adrenocorticotropic hormone and androgens.
Across analyses, CRENESSITY was generally well tolerated through two years of treatment in pediatric patients, with no new safety signals observed during long‑term follow‑up.
These analyses build on previously presented results showing that CRENESSITY enabled substantial, sustained reductions in mean GC dose over two years without compromising androgen control. Reduced GC exposure was associated with sustained improvements in clinical outcomes linked to long‑term, supraphysiologic GC use, including insulin resistance, weight and body mass index. These findings suggest a reduction in cardiometabolic risk in pediatric patients with classic CAH.
Presentations at the ENDO 2026 annual meeting included:
CAHtalyst Adult Study Two-Year Results
Title: Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst Adult Study (Oral Presentation #ORF32-07)
Authors: Oksana Hamidi, D.O., et al
Title: Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study (Poster Presentation #SUN-458)
Authors: Irina Bancos, M.D., et al
Title: A Cross-sectional Survey on Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia in the United States Participating in CAHtalyst Adult Open-Label Extension Study (Poster Presentation #SUN-467)
Authors: Sonal Vaid, M.D., et al
Title: Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in CAHtalyst Adult Study (Poster Presentation #SUN-468)
Authors: Maria Vogiatzi, M.D., et al
CAHtalyst Pediatric Study Two-Year Results
Title: Characterization of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Who Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont (Oral Presentation #ORF32-05)
Authors: Maria Vogiatzi, M.D., et al
Title: Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SAT-465)
Authors: Natalie Nokoff, M.D., et al
Title: Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SUN-465)
Authors: Kyriakie Sarafoglou, M.D., et al
Additional Presentations
Title: Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry ("New Therapies and Perspectives for Congenital Adrenal Hyperplasia and Adrenal Insufficiency" Rapid Fire Presentation #ORF32-02 and Poster Presentation #MON-495)
Authors: Oksana Lekarev, D.O., et al
Title: Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11β-Hydroxylase Deficiency: A Case Series (Poster Presentation #SAT-466)
Authors: Kyriakie Sarafoglou, M.D., et al
Title: A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia (Poster Presentation #SAT-459)
Authors: Ahmed Khattab, M.D., et al
About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.
Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at supraphysiologic doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with supraphysiologic GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to cardiometabolic and fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).
About CRENESSITY® (crinecerfont)
CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.
CRENESSITY comes in capsules and an oral solution. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.
About the CAHtalyst® Studies
The Phase 3 CAHtalyst global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY® (crinecerfont) in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients.
The CAHtalyst Pediatric study included 103 pediatric patients four to 17 years of age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved.
The CAHtalyst Adult study included 182 adult patients 18 to 58 years of age. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved.
Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing.
Important Information
Approved Uses
CRENESSITY® (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
IMPORTANT SAFETY INFORMATION
Do not take CRENESSITY if you:
Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.
CRENESSITY may cause serious side effects, including:
Allergic reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.
Risk of Sudden Adrenal Insufficiency or Adrenal Crisis with Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.
Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.
The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds.
These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.
Please see full Prescribing Information.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, CRENESSITY and CAHtalyst are registered trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH, including its potential to help address abnormal growth in pediatric patients with CAH by slowing bone age progression and improving predicted adult height in patients with advanced bone age at baseline; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of CRENESSITY; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.
Filing represents another important step in advancing Coosa, the largest and most developed graphite deposit in the contiguous United States
CENTENNIAL, Colo.--(BUSINESS WIRE)--Westwater Resources, Inc. (NYSE American: WWR), an energy technology and battery-grade natural graphite company (“Westwater” or the “Company”), today announced that it has submitted a Section 404 permit application to the U.S. Army Corps of Engineers for the Company’s Coosa Graphite Deposit in Coosa County, Alabama.
“Submission of the Section 404 permit application reflects continued progress in advancing Coosa through the permitting process,” said Frank Bakker, President and Chief Executive Officer of Westwater Resources.
Share The Section 404 permit application, submitted under the Clean Water Act, represents an important step in the permitting process for Coosa. The application relates to certain potential impacts to water associated with future development activities at the project site.
“Submission of the Section 404 permit application reflects continued progress in advancing Coosa through the permitting process,” said Frank Bakker, President and Chief Executive Officer of Westwater Resources. “Coosa is intended to serve as a future domestic feedstock source for our Kellyton Graphite Plant, supporting our objective of developing a secure U.S. vertically-integrated supply of battery-grade graphite.”
The Section 404 application follows the Company’s previously announced permit application filed earlier this year with the Alabama Department of Environmental Management (“ADEM”). Together, these permitting steps support Westwater’s continued advancement of Coosa through environmental review and permitting.
Coosa is listed on the federal FAST-41 Permitting Dashboard, which provides a publicly available timetable for environmental review and permitting activities. Westwater expects to continue advancing Coosa in alignment with the FAST-41 process and currently anticipates evaluating a final investment decision for the Coosa project following completion of the broader permitting process.
The Coosa Graphite Deposit is located approximately 30 miles from Westwater’s Kellyton Graphite Plant in east-central Alabama. Coosa is the largest and most developed graphite deposit in the contiguous United States and will provide a long-term domestic source of natural flake graphite feedstock, while Kellyton is being developed to process natural flake graphite into battery-grade graphite. Together, these assets support Westwater’s vertically-integrated, mine-to-market strategy of developing U.S.-based graphite production capacity for domestic battery supply chains.
About Westwater Resources, Inc.
Westwater Resources, Inc. (NYSE American: WWR) is a critical minerals and energy technology company advancing a vertically integrated, mine-to-market platform for battery-grade natural graphite in the United States. The Company’s platform is anchored by the Coosa Graphite Deposit in Alabama, the largest natural flake graphite deposit in the contiguous United States, and the Kellyton Graphite Plant, a processing facility designed to produce coated spherical purified graphite (CSPG), a key material used in lithium-ion battery anodes. For more information, visit WestwaterResources.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words and phrases such as “important step,” “advancing,” “largest and most developed,” “potential impacts,” “future development,” “continued progress,” “intended to serve,” “continued advancement,” “expects,” “continued advancing,” “currently anticipates,” “will provide,” “designed to produce,” and other similar words and phrases. Forward looking statements include, among other things, statements concerning operational developments including the construction of the Kellyton Graphite Plant, the development of the Coosa Graphite Deposit and its inclusion on the federal FAST-41 dashboard, and the costs, schedules, production and economic projections associated with both of them. The Company cautions that there are factors that could cause actual results to differ materially from the forward-looking information that has been provided.
The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of the Company; accordingly, there can be no assurance that such suggested results will be realized. Those uncertainties and other factors are discussed in Westwater’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent securities filings, and they could cause actual results to differ materially from management expectations.
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Zebra Technologies Corporation (NASDAQ: ZBRA), a global leader in digitizing and automating workflows to deliver intelligent operations, today announced its inclusion in the Wall Street Journal's inaugural Best Companies for the Future report. Zebra was ranked 10th in the category of AI readiness and 76th overall among S&P 500 companies. “We are proud to be recognized as a leader in the next era of AI-driven innovation,” said Tom Bianculli, Chief Technol.
Warren Buffett stepped down as CEO of Berkshire Hathaway (NYSE: BRK-B | BRK-B Price Prediction) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire. The “Oracle of Omaha” left his successor, Greg Abel, with a very concentrated portfolio: 70% of Berkshire’s $381 billion portfolio is invested in just seven stocks. Abel, who has served as vice chair overseeing non-insurance operations, officially took over as CEO on January 1, 2026. At 95 years old, Buffett isn’t fully retiring—he will remain chair of the board and plans to continue coming to the Omaha headquarters as much as before. However, he has stated he will be “going quiet” and leaving all decision-making to Abel.
One thing is for sure: the new CEO got to work in the first quarter, and 16 companies were eliminated, leaving just 26 stocks in the Berkshire Hathaway portfolio. In addition, Abel stunned the world as the company made its first major acquisition of a publicly traded company in years, buying homebuilder Taylor Morrison (NYSE: TMHC). The deal was priced at $72.50 per share in an all-cash transaction, implying an equity value of $6.8 billion and an enterprise value of $8.5 billion, including the homebuilder’s net debt. The agreement, one of the first major acquisitions under Abel, delivers a 24% premium to the target’s prior stock price. It is expected to close in the second half of the year, with Taylor Morrison continuing to operate under its existing management team. Before Taylor Morrison, the company’s last major buyout of an entire publicly traded company was Alleghany, which was acquired for $11.6 billion in 2022.
After the portfolio purge and the first acquisition since the purchase of OxyChem from Occidental Petroleum, just four stocks now make up 53.8% of the Berkshire Hathaway portfolio. Of the four stocks, only one saw any selling in the first quarter. However, the sale was quite minor, reducing their massive investment by less than 1%.
Why do we cover Berkshire Hathaway stocks? Few investors have the results and reputation that Buffett has garnered over the past 60 years. Though he has stepped away from the CEO chair, his impact and investment guidelines are likely to remain in place long after he is gone. While investing has evolved since Buffett took control of Berkshire Hathaway in 1965, buying good companies with products and services recognized worldwide and paying dividends will always remain a timeless approach.
Here are the four companies that now make up 53.8% of Berkshire Hathaway. All are rated Buy at top Wall Street firms we cover.
American Express American Express (NYSE: AXP) is an American bank holding company and multinational financial services corporation specializing in payment cards. The stock pays a dividend yield of 1.07%. American Express is a globally integrated payments company operating card-issuing, merchant-acquiring, and card network businesses.
The company offers products and services to customers worldwide, including consumers, small businesses, mid-sized companies, and large corporations. Its segments include:
U.S. Consumer Services, which offers travel and lifestyle services, as well as banking and non-card financing products. Commercial Services offers payment, expense management, banking, and non-card financing products. International Card Services provides services to international customers, including travel and lifestyle services, and manages certain international joint ventures and its loyalty coalition business. Global Merchant and Network Services operates a payments network that processes and settles card transactions, acquires merchants, and provides multichannel marketing programs, capabilities, services, and data analytics. Berkshire Hathaway owns 151,610,700 shares, 22% of American Express’s float and 14.2% of the portfolio.
Goldman Sachs has a Buy rating with a $400 target price.
Apple Apple (NASDAQ: AAPL) designs, develops, and sells consumer electronics, computer software, and online services, offering a small dividend of 0.35%. It is almost incomprehensible that the legacy technology giant, even after a recent fourth-quarter sale of 10 million shares and a surge in sales over the past two years, still holds a 227,917,808-share position that accounts for 21.8% of the Berkshire Hathaway portfolio, which holds 1.6% of Apple’s stock.
The company offers:
The iPhone, a line of smartphones Mac, a line of personal computers iPad, a line of multi-purpose tablets Wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod Apple also offers AppleCare support and cloud services, and operates various platforms, including the App Store, which enables customers to discover and download applications and digital content, such as books, music, videos, games, and podcasts.
In addition, the company offers various services, such as:
Apple Arcade, a game subscription service Apple Fitness+, a personalized fitness service Apple Music, which gives users a curated listening experience with on-demand radio stations Apple News+, a subscription news and magazine service Apple TV+, which offers exclusive original content Apple Card, a co-branded credit card Apple Pay, a cashless payment service Wedbush has an Outperform rating with a $400 target price.
Bank of America While Buffett trimmed his position in a big way over the past two years, this quality financial giant remains an exceptional long-term holding with a solid 2% dividend yield. Bank of America (NYSE: BAC) is a bank holding company that reported impressive Q4 results. Berkshire Hathaway owns 513,624,165 shares, which is 8.3% of the portfolio and 7.2% of the float. Berkshire did lower its Bank of America position in Q1 2026, but only modestly. According to the Q1 2026 13F filing, it was reduced by just 0.71%, a tiny cut compared to other positions.
Its segments include:
Consumer Banking offers a range of credit, banking, and investment products and services to consumers and small businesses. Global Wealth & Investment Management (GWIM) comprises two businesses: Merrill Wealth Management, which offers tailored solutions to meet clients’ needs through a comprehensive suite of investment management, brokerage, banking, and retirement products. Bank of America Private Bank provides comprehensive wealth management solutions. Global Banking offers a range of lending-related products and services, including integrated working capital management and treasury solutions, as well as underwriting and advisory services. Global Markets offers sales and trading services, as well as research services, to institutional clients across fixed income, credit, currency, commodity, and equity markets. UBS has a Buy rating with a $63 target price.
Coca-Cola Coca-Cola (NYSE: KO) is an American multinational corporation founded in 1892. This company remains a top long-time holding of Buffett. Berkshire owns 400 million shares, representing 9.3% of the float and 9.7% of the portfolio. The stock pays a dependable 2.46% dividend.
Coca-Cola is the world’s largest beverage company, offering consumers more than 500 sparkling and still brands. Led by Coca-Cola, one of the world’s most valuable and recognizable brands, the portfolio features 20 billion-dollar brands, including:
Diet Coke Coca-Cola Light Coca-Cola Zero Sugar Caffeine-free Diet Coke Cherry Coke Fanta Orange Fanta Zero Orange Fanta Zero Sugar Fanta Apple Sprite Sprite Zero Sugar Simply Orange Simply Apple Simply Grapefruit Fresca Schweppes Dasani Fuze Tea Glacéau Smartwater Glacéau Vitaminwater Gold Peak Ice Dew Powerade Topo Chico Minute Maid Globally, it is the top provider of sparkling beverages, ready-to-drink coffees, juices, and juice drinks. Through the world’s most extensive beverage distribution system, consumers in more than 200 countries enjoy the company’s beverages at a rate of over 1.9 billion servings per day. And remember that the company owns 19.5% of Monster Beverage (NASDAQ: MNST), which continues to deliver strong financial results.
Citigroup has a Buy rating with a $91 target price.
Ryan Yost appointed Division President, Global Flexible Packaging Solutions
Kate Pearlman appointed Senior Vice President, Investor Relations & Treasury
, /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced the appointments of Ryan Yost as Division President, Global Flexible Packaging Solutions, and Kate Pearlman as Senior Vice President, Investor Relations & Treasury.
Ryan Yost joins Amcor as Division President, Global Flexible Packaging Solutions.
Kate Pearlman joins Amcor as Senior Vice President, Investor Relations & Treasury. With 25 years of leadership roles at Avery Dennison, Ryan brings proven success in delivering consistent, profitable organic growth, most recently as President of Avery Dennison's global $6 billion Materials Group. He previously held various senior leadership roles spanning commercial, operations, supply chain and material science responsibilities. Ryan will accelerate Amcor's organic growth strategy across the Global Flexible Packaging Solutions platform, building on the business' leadership positions in attractive end markets including healthcare, protein, pet food, liquids, beauty and personal care and food service. He will be based in the U.S.
Kate has more than 20 years of experience in investor relations, global treasury and risk management leadership at Fortune 200 companies. She joins Amcor from Lowe's, where she held the role of Vice President, Investor Relations and Treasurer. Kate will lead Amcor's global investor relations function and will also assume responsibility for Amcor's treasury operations. In this expanded role, she will strengthen alignment across capital market management, value creation and shareholder engagement. Kate will report to Stephen Scherger, Executive Vice President and Chief Financial Officer, and the role will be based in the U.S.
"Ryan and Kate are exceptional leaders with proven track records of driving growth, building high-performing teams and translating strategy into results across large, global organizations," said Peter Konieczny, Amcor Chief Executive Officer. "I am highly confident in Amcor's business, strategy and ability to deliver for our customers and shareholders. Ryan and Kate bring the right expertise to help us build momentum, and we're excited to welcome them as we position Amcor for its next phase of growth."
Ryan succeeds Fred Stephan, who is retiring from Amcor, and Kate succeeds Tracey Whitehead, who has chosen to remain in Australia and pursue opportunities there. Fred and Tracey will remain with Amcor as advisors through Dec. 31, 2026, to ensure a smooth transition.
"Fred and Tracey have each made a lasting impact on Amcor, and I thank them for their outstanding leadership, partnership and unwavering commitment to the company," Peter said. "Fred has been instrumental in strengthening our global flexibles business and positioning the business for continued strong performance, while Tracey has served as a highly respected and trusted leader in our engagement with the investment community."
About Amcor
Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons and closures that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC
www.amcor.com | LinkedIn | YouTube
Developed in partnership with Club Med, the project will bring the global hospitality brand’s signature all-inclusive experience back to U.S. shores while expanding VICI's experiential real estate portfolio.
ST. CROIX, U.S. Virgin Islands & NEW YORK--(BUSINESS WIRE)--Club Med, the pioneer of the all-inclusive concept with nearly 60 resorts in some of the world’s most desired vacation destinations, and VICI Properties Inc. (NYSE: VICI), an S&P 500 experiential real estate investment trust, announced today the acquisition and planned redevelopment of the iconic Carambola Beach Resort, located in the U.S. Virgin Islands, marking the return of Club Med to U.S. shores. The future Club Med St. Croix will reinforce the hospitality brand’s leadership in the premium all-inclusive category, while bringing a renewed spirit to the destination’s most historic beachfront property.
The project is a result of a partnership between Club Med and VICI. Following VICI’s acquisition of the Carambola Beach Resort, VICI has entered into a long-term triple-net lease with Club Med, and will fund the resort’s redevelopment, elevating the property to Club Med’s Exclusive Collection standards. Club Med will run the future operations of the historic 150-key resort, transforming it into a model for sustainable, culturally rich and all-inclusive hospitality in the region.
“The U.S. Virgin Islands represent an exciting new chapter for Club Med,” said Carolyne Doyon, President and CEO of Club Med North America and the Caribbean. “For more than seven decades, we’ve welcomed North American travelers to our destinations around the world, and now we’re bringing that experience back home. With St. Croix’s natural beauty, strong community spirit, and deep cultural roots, together with the longstanding legacy of this hotel, this project reflects our vision for thoughtful growth, and meaningful connection across the Americas.”
John Payne, President and COO of VICI, said, "We are very excited to begin our partnership with Club Med, a true pioneer of the premium all-inclusive resort experience and the brand leader in the category. Club Med's approach to growth aligns directly with how VICI partners with best-in-class experiential operators, and Carambola Beach Resort is an ideal asset to launch our relationship. We have tremendous respect for what the Club Med team has built, and we look forward to opportunities to support their continued growth across North America for years to come.”
An Iconic Setting Reimagined
Originally built in 1986 by philanthropist and conservation pioneer Laurance Rockefeller, Carambola Beach Resort reflects his enduring vision for the U.S. Virgin Islands, where hospitality and preservation exist in balance. Club Med’s redevelopment plans envision a comprehensive renovation that preserves the property’s natural beauty and historic roots.
The resort, nestled between a crescent beach and tropical rainforest, will be part of Club Med’s Exclusive Collection, the brand’s most refined portfolio of premium all-inclusive resorts, distinguished by elevated design, personalized service, and exceptional experiences in extraordinary settings.
A Flagship Destination and a U.S. Homecoming
Club Med St. Croix will mark the brand’s reentry onto U.S. soil and aims to attract travelers from the U.S., Canada, and around the world seeking a high quality, all-inclusive experience in a unique island setting. Beyond its touristic appeal, the resort will act as a key economic driver for St. Croix and the broader Virgin Islands, fueling job creation, local partnerships, and sustainable growth across the territory.
Empowering Local Opportunity: Economic Impact
Discussions with senior government officials have highlighted shared ambitions around local employment, education and training, business development, and responsible tourism.
Aligned with Club Med’s Happy to Care sustainability commitments, the project will target BREEAM and Green Globe certifications—benchmarks of environmental design and operational responsibility. Together, these efforts underscore Club Med’s longstanding focus on environmental performance and community stewardship.
“The arrival of the Club Med brand to the U.S. Virgin Islands marks another significant milestone in the continued economic growth and revitalization of our islands — particularly St. Croix — where tourism remains a key driver of opportunity and investment,” said Governor Albert Bryan Jr. “We are proud to welcome the Club Med team to the territory and look forward to growing this partnership as we continue elevating the U.S. Virgin Islands, celebrating our people and culture, and welcoming new and returning visitors to our beautiful shores.”
Once complete, the redevelopment is projected to generate approximately 200 direct jobs along with at least as many indirect opportunities. The resort is expected to further stimulate the local economy through collaborations with excursion operators, service providers, and local farmers and artisans, reinforcing the connection between tourism and the island’s broader community. Club Med plans to continue to engage with the local community in the upcoming months to share further details of the project.
Construction is expected to begin in summer 2026, followed by a targeted reopening in Q4 2027.
To learn more about Club Med’s existing footprint in North America, click here.
About Club Med
Club Med, founded in 1950 by Gérard Blitz, is the pioneer of the all-inclusive concept, operating nearly 60 premium resorts in stunning locations around the world including North and South America, Caribbean, Asia, Africa, Europe and the Mediterranean. Each Club Med resort features authentic local style and comfortably upscale accommodations, superior sports programming and activities, enriching children's programs, gourmet dining, and warm and friendly service by its world-renowned staff with legendary hospitality skills, an all-encompassing energy and diverse backgrounds.
Club Med operates in 40 countries spanning across 5 continents and continues to maintain its authentic Club Med spirit with an international staff of more than 23,000 employees from more than 110 different nationalities. Led by its pioneering spirit, Club Med continues to grow and adapt to each market with three to five new resort openings or renovations per year, including a new mountain resort annually.
For more information, visit www.clubmed.us, call 1-800-Club-Med (1-800-258-2633), or contact a preferred travel professional. For an inside look at Club Med, follow Club Med on Facebook, Instagram, and YouTube.
About VICI Properties Inc.
VICI Properties Inc. is an S&P 500® experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality, wellness, entertainment and leisure destinations, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas, three of the most iconic entertainment facilities on the Las Vegas Strip. VICI Properties owns 101 experiential assets across a geographically diverse portfolio consisting of 61 gaming properties and 40 other experiential properties across the United States and Canada. The portfolio is comprised of approximately 130 million square feet and features over 66,000 hotel rooms and over 700 restaurants, bars, nightclubs and sportsbooks. Its properties are occupied by industry-leading gaming, leisure and hospitality operators under long-term, triple-net lease agreements. VICI Properties has a growing array of real estate and financing partnerships with leading operators in other experiential sectors, including Cabot, Cain, Canyon Ranch, Chelsea Piers, Club Med, Great Wolf Resorts, Homefield, Kalahari Resorts and Lucky Strike Entertainment. VICI Properties also owns four championship golf courses and approximately 33 acres of undeveloped and underdeveloped land adjacent to the Las Vegas Strip. VICI Properties’ goal is to create the highest quality and most productive experiential real estate portfolio through a strategy of partnering with the highest quality experiential place makers and operators. For additional information, please visit www.viciproperties.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of the words “assumes,” “believes,” “estimates,” “expects,” “guidance,” “intends,” “plans,” “projects,” “will,” and similar expressions that do not relate to historical matters. All statements other than statements of historical fact are forward-looking statements. You should exercise caution in interpreting and relying on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond VICI’s control and could materially affect VICI’s actual results, performance, achievements, or VICI’s ability to achieve the benefits contemplated by the transaction. Other important risk factors that may affect VICI’s business, results of operations and financial position (including risks relating to VICI’s pending transactions) are detailed from time to time in VICI’s filings with the Securities and Exchange Commission. VICI does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.
Developed in partnership with VICI Properties, the resort will mark Club Med's return to U.S. shores, bringing Club Med's signature all-inclusive experience to the cultural heart of the Virgin Islands
, /PRNewswire/ -- Club Med, the pioneer of the all-inclusive concept with nearly 60 resorts in some of the world's most desired vacation destinations, and VICI Properties Inc. (NYSE: VICI), an S&P 500 experiential real estate investment trust, announced today the acquisition and planned redevelopment of the iconic Carambola Beach Resort, located in the U.S. Virgin Islands, marking the return of Club Med to U.S. shores. The future Club Med St. Croix will reinforce the hospitality brand's leadership in the premium all-inclusive category, while bringing a renewed spirit to the destination's most historic beachfront property.
The project is a result of a partnership between Club Med and VICI. Following VICI's acquisition of the Carambola Beach Resort, VICI has entered into a long-term triple-net lease with Club Med, and will fund the resort's redevelopment, elevating the property to Club Med's Exclusive Collection standards. Club Med will run the future operations of the historic 150-key resort, transforming it into a model for sustainable, culturally rich and all-inclusive hospitality in the region.
"The U.S. Virgin Islands represent an exciting new chapter for Club Med," said Carolyne Doyon, President and CEO of Club Med North America and the Caribbean. "For more than seven decades, we've welcomed North American travelers to our destinations around the world, and now we're bringing that experience back home. With St. Croix's natural beauty, strong community spirit, and deep cultural roots, together with the longstanding legacy of this hotel, this project reflects our vision for thoughtful growth, and meaningful connection across the Americas."
John Payne, President and COO of VICI, said, "We are very excited to begin our partnership with Club Med, a true pioneer of the premium all-inclusive resort experience and the brand leader in the category. Club Med's approach to growth aligns directly with how VICI partners with best-in-class experiential operators, and Carambola Beach Resort is an ideal asset to launch our relationship. We have tremendous respect for what the Club Med team has built, and we look forward to opportunities to support their continued growth across North America for years to come."
An Iconic Setting Reimagined
Originally built in 1986 by philanthropist and conservation pioneer Laurance Rockefeller, Carambola Beach Resort reflects his enduring vision for the U.S. Virgin Islands, where hospitality and preservation exist in balance. Club Med's redevelopment plans envision a comprehensive renovation that preserves the property's natural beauty and historic roots.
The resort, nestled between a crescent beach and tropical rainforest, will be part of Club Med's Exclusive Collection, the brand's most refined portfolio of premium all-inclusive resorts, distinguished by elevated design, personalized service, and exceptional experiences in extraordinary settings.
A Flagship Destination and a U.S. Homecoming
Club Med St. Croix will mark the brand's reentry onto U.S. soil and aims to attract travelers from the U.S., Canada, and around the world seeking a high quality, all-inclusive experience in a unique island setting. Beyond its touristic appeal, the resort will act as a key economic driver for St. Croix and the broader Virgin Islands, fueling job creation, local partnerships, and sustainable growth across the territory.
Empowering Local Opportunity: Economic Impact
Discussions with senior government officials have highlighted shared ambitions around local employment, education and training, business development, and responsible tourism.
Aligned with Club Med's Happy to Care sustainability commitments, the project will target BREEAM and Green Globe certifications—benchmarks of environmental design and operational responsibility. Together, these efforts underscore Club Med's longstanding focus on environmental performance and community stewardship.
"The arrival of the Club Med brand to the U.S. Virgin Islands marks another significant milestone in the continued economic growth and revitalization of our islands — particularly St. Croix — where tourism remains a key driver of opportunity and investment," said Governor Albert Bryan Jr. "We are proud to welcome the Club Med team to the territory and look forward to growing this partnership as we continue elevating the U.S. Virgin Islands, celebrating our people and culture, and welcoming new and returning visitors to our beautiful shores."
Once complete, the redevelopment is projected to generate approximately 200 direct jobs along with at least as many indirect opportunities. The resort is expected to further stimulate the local economy through collaborations with excursion operators, service providers, and local farmers and artisans, reinforcing the connection between tourism and the island's broader community. Club Med plans to continue to engage with the local community in the upcoming months to share further details of the project.
Construction is expected to begin in summer 2026, followed by a targeted reopening in Q4 2027.
To learn more about Club Med's existing footprint in North America, click here and to partner with Club Med on other potential developments, visit clubmeddevelopment.com.
ABOUT CLUB MED
Club Med, founded in 1950 by Gérard Blitz, is the pioneer of the all-inclusive concept, operating nearly 60 premium resorts in stunning locations around the world including North and South America, Caribbean, Asia, Africa, Europe and the Mediterranean. Each Club Med resort features authentic local style and comfortably upscale accommodations, superior sports programming and activities, enriching children's programs, gourmet dining, and warm and friendly service by its world-renowned staff with legendary hospitality skills, an all-encompassing energy and diverse backgrounds.
Club Med operates in 40 countries spanning across 5 continents and continues to maintain its authentic Club Med spirit with an international staff of more than 23,000 employees from more than 110 different nationalities. Led by its pioneering spirit, Club Med continues to grow and adapt to each market with three to five new resort openings or renovations per year, including a new mountain resort annually.
For more information, visit www.clubmed.us, call 1-800-Club-Med (1-800-258-2633), or contact a preferred travel professional. For an inside look at Club Med, follow Club Med on Facebook, Instagram, and YouTube.
About VICI Properties Inc.
VICI Properties Inc. is an S&P 500® experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality, wellness, entertainment and leisure destinations, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas, three of the most iconic entertainment facilities on the Las Vegas Strip. VICI Properties owns 101 experiential assets across a geographically diverse portfolio consisting of 61 gaming properties and 40 other experiential properties across the United States and Canada. The portfolio is comprised of approximately 130 million square feet and features over 66,000 hotel rooms and over 700 restaurants, bars, nightclubs and sportsbooks. Its properties are occupied by industry-leading gaming, leisure and hospitality operators under long-term, triple-net lease agreements. VICI Properties has a growing array of real estate and financing partnerships with leading operators in other experiential sectors, including Cabot, Cain, Canyon Ranch, Chelsea Piers, Club Med, Great Wolf Resorts, Homefield, Kalahari Resorts and Lucky Strike Entertainment. VICI Properties also owns four championship golf courses and approximately 33 acres of undeveloped and underdeveloped land adjacent to the Las Vegas Strip. VICI Properties' goal is to create the highest quality and most productive experiential real estate portfolio through a strategy of partnering with the highest quality experiential place makers and operators. For additional information, please visit www.viciproperties.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of the words "assumes," "believes," "estimates," "expects," "guidance," "intends," "plans," "projects," "will," and similar expressions that do not relate to historical matters. All statements other than statements of historical fact are forward-looking statements. You should exercise caution in interpreting and relying on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond VICI's control and could materially affect VICI's actual results, performance, achievements, or VICI's ability to achieve the benefits contemplated by the transaction. Other important risk factors that may affect VICI's business, results of operations and financial position (including risks relating to VICI's pending transactions) are detailed from time to time in VICI's filings with the Securities and Exchange Commission. VICI does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.
Club Med Media Contacts:
Malaika Hollis
Alliance Connection
[email protected]
VICI Investor Contacts:
[email protected]
(646) 949-4631
Or
David Kieske
EVP, Chief Financial Officer
[email protected]
Moira McCloskey
SVP, Capital Markets
[email protected]
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2026) - Southern Silver Exploration Corp. (TSXV: SSV) ("Southern Silver" or the "Company") has closed the first tranche of its previously reported non-brokered private placement by issuing 4,000,181 common shares of the Company (the "Shares") at a price of $0.55 per Share for gross proceeds of $2,200,099.55 (the "Offering").
In accordance with National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"), the Shares were sold to Canadian purchasers pursuant to the listed issuer financing exemption under Part 5A of NI 45-106, as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption") and sold in offshore jurisdictions. The Shares are immediately freely tradeable in accordance with applicable Canadian securities legislation.
There is an amended and restated offering document (the "Amended Offering Document") related to this Offering that can be accessed under the Company's profile at www.sedarplus.ca and on the Company's website at https://southernsilverexploration.com/.
In connection with the first tranche closing, the Company paid aggregate finders' fees of $132,005.97 and issued 240,010 non-transferable common share purchase warrants ("Finder Warrants"), with each Finder Warrant exercisable to purchase one Share at a price of $0.70 for a period of 36 months. The Finder Warrants and the Shares issuable upon the exercise of the Finder Warrants carry a legend restricting trading of the securities until October 13, 2026. The closing of the Offering remains subject to the final approval of the TSX Venture Exchange.
Proceeds of the Offering will be used for the advancement of the Cerro Las Minitas project as well as for working capital and general corporate purposes. Advancement of Cerro Las Minitas includes infill drilling of up to 12,500m in Phase 1 with the objective of upgrading the resource classification of a subset of near-surface, high-grade mineralization in the Puro Corazon target, which will allow greater optionality for potential development of the project. Other work will include an update of the mineral resource estimate based on the most recent drilling at Puro Corazon, scheduled for Q2 2026 and the advancement of several engineering opportunities identified in the 2024 preliminary economic assessment ("PEA") of the project.
As currently modelled, the Cerro Las Minitas project features a large-scale underground mining operation with robust project economics and high gross revenues in a well located and mining friendly jurisdiction. Recent drill testing of the Puro Corazon claim continues to demonstrate a potential for near-term resource growth, capital and mining efficiency gains in modelled mining scenarios and overall improvements in modelling of the project.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor was there any sale of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Shares referred to in this news release will not be, and have not been, registered under the U.S. Securities Act and may not be offered or sold within the United States or to, or for the account or benefit of, a U.S. person, absent registration or any applicable exemption from registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.
About Southern Silver Exploration Corp.
Southern Silver Exploration Corp. is an exploration and development company with a focus on the discovery of mineral deposits either directly or through joint-venture relationships in mineral properties in major jurisdictions. Our specific emphasis is developing the 100% owned Cerro Las Minitas silver-lead-zinc project located in the heart of Mexico's Faja de Plata, which hosts multiple world-class mineral deposits such as Penasquito, Los Gatos, San Martin, Naica and Pitarrilla. We have assembled a team of highly experienced technical, operational and transactional professionals to support our exploration efforts in developing the Cerro Las Minitas project into a premier, high-grade, silver-lead-zinc mine. Located in the same State as the Cerro Las Minitas property is the Nazas, gold-silver property. Our property portfolio also includes the Oro porphyry copper-gold project, and the Hermanas gold-silver vein project. Drill permits for the Hermanas project have been received and work is pending finalization of a work program and drill availability, both located in southern New Mexico, USA.
Robert Macdonald, MSc. P. Geo, is an officer of Southern Silver Exploration Corp. and is a Qualified Person as defined by National Instrument 43-101. Mr. Macdonald directly supervised the collection of the technical data from the Cerro Las Minitas Project and has reviewed and approved the technical information within this news release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. Forward-looking statements in this news release include the amount of the Offering, final TSX Venture Exchange approval of the Offering, plans to advance and develop the Cerro Las Minitas property including updating the mineral resource estimate followed by an update of the PEA, and expectations regarding the Cerro Las Minitas project having robust project economics and potential for high gross revenues. These statements are based on a number of assumptions, including, but not limited to, general economic conditions, interest rates, commodity markets, regulatory and governmental approvals for the Company's projects, and the availability of financing for the Company's development projects on reasonable terms. Factors that could cause actual results to differ materially from those in forward looking statements include the timing and receipt of government and regulatory approvals, and continued availability of capital and financing and general economic, market or business conditions. The Company provides no assurance that forward-looking statements or forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements and information. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward- looking information, whether as a result of new information, changing circumstances, or otherwise.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301411
Source: Southern Silver Exploration Corp.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK--(BUSINESS WIRE)--American Express (NYSE: AXP) today announced a proposed acquisition of TheFork, a leading online restaurant reservation and management platform in Europe, from Tripadvisor, Inc. (NASDAQ: TRIP), growing its dining offering in the region.
Dining is one of the most important ways people engage with our brand
Share TheFork connects millions of diners with more than 50,000 restaurants across 11 European countries through its restaurant management, booking and customer engagement platform, alongside a consumer-facing restaurant discovery and reservation app and website.
The proposed acquisition builds on American Express’ broader dining strategy and its successful acquisitions of digital dining platforms Resy and Tock. Together, these platforms are expected to expand American Express’ dining network to 75,000 bookable venues1.
With the proposed acquisition of TheFork, American Express would grow its dining offerings in Europe and strengthen its ability to provide access for Card Members and diners to sought-after restaurants, while supporting the continued growth of its international business, a major driver of the company’s overall growth.
“Dining is one of the most important ways people engage with our brand,” said Rafa Marquez, President of International Card Services at American Express. “Over time, the proposed acquisition would help us enrich our differentiated Membership Model by offering Card Members more ways to discover, book and access great restaurants, while helping our partners reach more diners and grow their businesses. TheFork has built a successful platform across Europe with strong relationships throughout the restaurant industry that would complement our existing capabilities. We look forward to supporting TheFork’s continued growth and building on its success as we strengthen our dining presence across Europe.”
"TheFork was created to help restaurants thrive and to make it easier for diners to discover and enjoy great restaurants,” said Almir Ambeskovic, Chief Executive Officer of TheFork. “With Tripadvisor's support, we've built one of Europe's leading dining platforms. American Express shares our commitment to innovation, service and hospitality. Together, we have a unique opportunity to accelerate our mission, bringing even more value to restaurants while creating richer and more seamless experiences for millions of diners across Europe."
Founded in 2007, TheFork provides restaurants with reservation management, guest engagement and operational tools designed to help restaurants optimize their businesses while delivering a seamless discovery and booking experience for diners.
Following the closing of the potential transaction, TheFork would continue to operate under its existing leadership team while benefiting from the global reach and powerful backing of American Express.
The proposed transaction is expected to close before the end of 2026, subject to labor consultation and customary conditions, including regulatory approvals. Under the terms of the proposal, American Express will acquire TheFork from Tripadvisor for $700 million in cash, subject to customary adjustments.
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. The forward-looking statements, which include current expectations regarding the transactions and future operations, among other matters, contain words such as “believe,” “expect,” “intend,” “plan,” “aim,” “will,” “may,” “should,” “could,” “would,” “continue” and similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company undertakes no obligation to update or revise any forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements, include, but are not limited to: the parties’ ability to satisfy the closing conditions, including completion of a labor consultation process and receipt of regulatory approvals, and consummate the transaction; the underlying assumptions related to the transaction proving to be inaccurate or unrealized; and American Express’ ability to integrate TheFork and benefit from and expand its platform, tools and capabilities, which will depend in part on management’s decisions regarding future operations, strategies and business initiatives. A further description of these and other risks and uncertainties can be found in American Express’ Annual Report on Form 10-K for the year ended December 31, 2025 and its other reports filed with the SEC.
ABOUT AMERICAN EXPRESS
American Express (NYSE: AXP) is a global payments and premium lifestyle brand powered by technology. Our colleagues around the world back our customers with differentiated products, services, and experiences that enrich lives and build business success.
Founded in 1850 and headquartered in New York, American Express’ brand is built on trust, security, service, and a rich history of delivering innovation and Membership value for our customers. We seek to provide the world’s best customer experience every day to a broad range of consumers, small and medium-sized businesses, and large corporations, and we build and manage relationships with millions of merchants across our global network.
For more information about American Express, visit americanexpress.com, americanexpress.com/en-us/newsroom/, and ir.americanexpress.com.
ABOUT THEFORK
TheFork is a leading online restaurant marketplace and technology platform in Europe, connecting diners with restaurants through its consumer marketplace and software solutions. Founded in 2007, TheFork helps diners discover and book restaurants while enabling restaurant partners to attract guests, optimize operations and drive sustainable growth. TheFork partners with more than 50,000 restaurants across 11 European countries and serves millions of diners through its mobile app and website.
1 Venue figures are based on American Express and TheFork internal company records as of June 2026. Methodologies may differ across platforms, and combined figures reflect company estimates at the time of announcement
Transaction highlights the value of Tripadvisor's portfolio and enables greater focus on experiences
, /PRNewswire/ -- Tripadvisor, Inc. (NASDAQ: TRIP) (the "Company") today announced it has entered into a put option agreement to sell TheFork, its online restaurant reservation and management platform in Europe, to American Express for $700 million in an all-cash transaction.
The agreement follows Tripadvisor's February 2026 announcement that it would explore strategic alternatives for TheFork. It recognizes the value created in the business over more than a decade, and allows Tripadvisor to focus even more fully on its Experiences strategy.
tripadvisor "This agreement reflects two things we believe deeply: the tangible value across Tripadvisor Group's portfolio and our ongoing focus on the opportunity we see ahead in Experiences," said Matt Goldberg, CEO, Tripadvisor Group. "We're proud of what we've built with TheFork and grateful for the team's work to secure a leading position in European dining. I'm confident that we've found an ideal home for them and look forward to expanding our relationship with American Express in the future."
The transaction is expected to provide Tripadvisor with significant flexibility to accelerate its capital return policy, maintain a well-capitalized balance sheet, and continue investing in its Experiences business to drive shareholder value. The companies also see opportunities to build on their existing relationship and deliver additional value to travelers over time.
"In addition to welcoming TheFork to the American Express family, we're excited about the opportunity to deepen our relationship with Tripadvisor going forward," said Stephen Squeri, Chairman and CEO, American Express. "By building on our shared strengths across dining, travel, and experiences, we have opportunities to create even greater value for customers and partners."
The proposed transaction is expected to close before the end of 2026, subject to labor consultation and customary closing conditions, including regulatory approvals. The Company anticipates minimal tax cost from the sale of TheFork, with net proceeds expected to closely approximate the gross proceeds. Potential uses of proceeds include share repurchases, debt paydown, or inorganic investment within the experiences category.
As of the first quarter of 2026, the Company's last reported period, the last twelve-month revenue for TheFork was $232 million and adjusted EBITDA for TheFork segment for the same period was $28 million.
Advisors
Goldman Sachs served as financial advisor and Goodwin Procter LLP and Reed Smith LLP served as legal advisors to Tripadvisor and TheFork.
Note on Segment Adjusted EBITDA
We refer to segment adjusted EBITDA as a measure of segment profitability because it is the measure of profit or loss for our reportable segments provided to our Chief Operating Decision Maker (CODM) in accordance with U.S. GAAP for segment reporting. Segment adjusted EBITDA is a key performance measure used by our CODM and Board of Directors to evaluate our individual operating segments. We define adjusted EBITDA as net income (loss) plus: (1) (provision) benefit for income taxes; (2) other income (expense), net; (3) depreciation and amortization; (4) stock-based compensation; (5) goodwill, long-lived asset, and intangible asset impairments; (6) legal reserves, settlements and other (including indirect tax reserves related to audit settlements and the impact of one-time changes resulting from enacted indirect tax legislation); (7) restructuring and other related reorganization costs; (8) transaction related expenses (including non-operational costs related to significant shareholder activism, which includes third-party advisory, legal, and other professional fees); and (9) non-recurring expenses and income unusual in nature or infrequently occurring.
About Tripadvisor, Inc.
The Tripadvisor Group connects people to experiences worth sharing, and aims to be the world's most trusted source for travel and experiences. We leverage our brands, technology, and capabilities to connect our global audience with partners through rich content, travel guidance, and two-sided marketplaces for experiences, restaurants, and other travel categories such as hotels. The subsidiaries of Tripadvisor, Inc. (Nasdaq: TRIP), include a portfolio of travel brands and businesses, including Tripadvisor, Viator, and TheFork.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding the proposed sale of Tripadvisor's TheFork business to American Express, the anticipated benefits, related agreements and timing of the transaction and potential uses of proceeds. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.
Key factors that could cause such differences include: whether or when the required employee works council consultation processes are completed; the ability of the parties to successfully execute a definitive purchase agreement following exercise of the put option; the satisfaction of closing conditions, including obtaining regulatory and antitrust approvals; difficulties or unexpected costs relating to segregating the integrated technology data and platform of TheFork from our retained operations and anticipated benefits for Tripadvisor as a result of the proposed transaction do not fully materialize; risks related to disruption of management time; the operational risk of running our core business without the integrated data platform of TheFork; and the potential for material adjustments to net working capital or unforeseen tax consequences related to the divestiture. Tripadvisor expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect any change in Tripadvisor's expectations with regard thereto or any change in events, conditions or circumstances on which such statement is based. Please refer to the publicly filed documents of Tripadvisor, including its most recent Forms 10-K and 10-Q, as such risk factors may be amended, supplemented or superseded from time to time by other reports Tripadvisor subsequently filed with the SEC, for additional information about Tripadvisor and about the risks and uncertainties related to Tripadvisor's business which may affect the statements in this release.
Credit card is seen in front of displayed American Express logo in this illustration taken, July 15, 2021. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesJune 15 (Reuters) - American Express (AXP.N), opens new tab said on Monday it will buy restaurant booking platform TheFork from Tripadvisor (TRIP.O), opens new tab in an all-cash deal worth $700 million, sending shares of the online travel platform up 14% in premarket trading.
Activist investor Starboard Value had in October last year pressed for TheFork's sale, as Tripadvisor struggled to recover from pandemic-era disruptions and contend with heavy competition from rivals including Booking Holdings (BKNG.O), opens new tab and Airbnb (ABNB.O), opens new tab.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
For American Express, buying TheFork will expand its dining network to 75,000 bookable venues and bolster its international business, which has been its fastest-growing segment for many years. It also builds on its acquisitions of dining platforms Resy and Tock.
“Dining is one of the most important ways people engage with our brand,” said Rafa Marquez, president of international card services at American Express.
TheFork generated $232 million in revenue for the year ended March 31, a 25% jump from a year earlier, according to Tripadvisor's earnings report.
The restaurant management, booking and customer engagement platform connects millions of diners with more than 50,000 restaurants across 11 European countries, said American Express.
The deal is expected to close before the end of 2026 and TheFork will continue to operate under its existing leadership, it added.
Goldman Sachs served as financial adviser to Tripadvisor and TheFork.
Reporting by Arasu Kannagi Basil and Anshuman Tripathy in Bengaluru; Editing by Jonathan Ananda
Our Standards: The Thomson Reuters Trust Principles., opens new tab
MIAMI, FL AND HOLLYWOOD, FL / ACCESS Newswire / June 15, 2026 / HEICO Corporation (NYSE:HEI.A)(NYSE:HEI) today announced that its Board of Directors declared a $.13 per share semiannual cash dividend, an 8% increase from the prior semiannual cash dividend of $.12 per share, payable on all shares of its Common Stock and Class A Common Stock.
The dividend marks HEICO's 96th consecutive semiannual cash dividend since 1979.
The dividend is payable on July 15, 2026 to all shareholders of record on July 1, 2026.
Eric A. Mendelson and Victor H. Mendelson, HEICO's Co-Chairmen and Co-Chief Executive Officers, commented, "HEICO's future is exciting and we are proud of our financial results. As a result, our Board of Directors declared this 96th consecutive semiannual dividend. Our continued success is a direct result of our talented and dedicated HEICO Team Members around the world, and we are pleased that those participating in the Company's 401K plan will share in that success through this dividend in their plan accounts."
HEICO Corporation is engaged primarily in the design, production, servicing and distribution of products and services to certain niche segments of the aviation, defense, space, medical, telecommunications and electronics industries through its Hollywood, Florida-based Flight Support Group and its Miami, Florida-based Electronic Technologies Group. HEICO's customers include a majority of the world's airlines and overhaul shops, as well as numerous defense and space contractors and military agencies worldwide, in addition to medical, telecommunications and electronics equipment manufacturers. For more information about HEICO, please visit our website at https://www.heico.com.
Certain statements in this press release constitute forward-looking statements, which are subject to risks, uncertainties and contingencies. HEICO's actual results may differ materially from those expressed in or implied by those forward-looking statements. Factors that could cause such differences include, among others: the severity, magnitude and duration of public health threats; our liquidity and the amount and timing of cash generation; lower commercial air travel, airline fleet changes or airline purchasing decisions, which could cause lower demand for our goods and services; product specification costs and requirements, which could cause an increase in our costs to complete contracts; governmental and regulatory demands, export policies and restrictions, reductions in defense, space or homeland security spending by U.S. and/or foreign customers or competition from existing and new competitors, which could reduce our sales; our ability to introduce new products and services at profitable pricing levels, which could reduce our sales or sales growth; product development or manufacturing difficulties, which could increase our product development and manufacturing costs and delay sales; cybersecurity events or other disruptions of our information technology systems could adversely affect our business; and our ability to make acquisitions, including obtaining any applicable domestic and/or foreign governmental approvals, and achieve operating synergies from acquired businesses; customer credit risk; interest, foreign currency exchange and income tax rates; and economic conditions, including the effects of inflation, within and outside of the aviation, defense, space, medical, telecommunications and electronics industries, which could negatively impact our costs and revenues. Parties receiving this material are encouraged to review all of HEICO's filings with the Securities and Exchange Commission including, but not limited to filings on Form 10-K, Form 10-Q and Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.
This investment supports continued growth in Generac's Commercial & Industrial business amid rising demand from data centers and mission-critical applications
, /PRNewswire/ -- Generac Holdings Inc. (NYSE: GNRC), a leading global designer, manufacturer and provider of energy technology solutions and other power products, announced the acquisition of a new facility in Belvidere, Illinois. The investment will significantly expand the company's packaging capacity for large-megawatt (MW) generators as demand continues to accelerate across key sectors.
In February, Generac acquired Enercon Engineering, Inc., adding specialized expertise in generator enclosure manufacturing. Building on this capability and in response to rising demand, the new facility will complement Enercon's operations by expanding capacity for enclosure assembly and final packaging, delivering shipment-ready units to customers.
"As demand for reliable backup power continues to grow — particularly from data centers and other mission-critical industries —expanding our capacity to deliver large-megawatt solutions is essential," said Erik Wilde, EVP and President, Domestic C&I at Generac. "This investment strengthens our ability to scale efficiently while maintaining the quality and speed our customers expect."
This investment adds to Generac's continued investments to scale its Commercial & Industrial (C&I) business, including expanded operations in Oshkosh, Wisconsin, and new facilities in Beaver Dam and Sussex, Wisconsin. These efforts are complemented by strategic initiatives such as collaboration with EPC Power and the acquisition of Enercon Engineering. Together, these investments continue to strengthen Generac's domestic manufacturing footprint and position the company to meet growing demand across key markets.
The Belvidere facility is strategically located, providing direct access to major interstate systems and enabling efficient transport of large-scale equipment. The new facility will add more than 100 new jobs when it opens in the first quarter of 2027.
About Generac
Generac is a total energy solutions company that empowers people to use energy on their own terms. Founded in 1959, Generac is a leading global designer, manufacturer, and provider of a wide range of energy technology solutions. The Company provides power generation equipment, energy storage systems, energy management devices & solutions, and other power products and services serving the residential, commercial, data center, telecom, rental, and industrial markets. Generac introduced the first affordable backup generator and later created the automatic home standby generator category. The Company's broad portfolio of energy technology offerings for homes and businesses enables its mission to Power a Smarter World and lead the evolution to more resilient, efficient, and innovative energy solutions.
The U.S. nuclear sector reached a historic technical milestone earlier this month when Antares Nuclear’s Mark-0 microreactor achieved criticality at Idaho National Laboratory (INL). The June 4 demonstration marked the first time a privately developed advanced reactor reached this state under the Department of Energy’s (DOE) Reactor Pilot Program (RPP). It also represented the first novel reactor design to go critical at INL in more than 40 years.
This event provides concrete validation that reactor concepts can move from design and analysis into physical testing on accelerated timelines. It also underscores the supporting role in the nuclear supply chain of established companies that deliver the specialized fuel and components required for these tests.
Key Takeaways Antares Nuclear’s microreactor became the first advanced design to complete a criticality test under the DOE RPP. BWX Technologies (BWXT) manufactured and supplied the reactor fuel that powered the successful test. The demonstration clears the way for Aalo Atomics to pursue its own criticality milestone later this summer with support from Flowserve (FLS), another established constituent of the VettaFi Nuclear Renaissance Index (NUKZX). What Happened at INL Antares conducted the test at INL using the Mark-0, a microreactor fueled with high-assay low-enriched uranium (HALEU). The reactor reached a self-sustaining nuclear chain reaction, but produced essentially no measurable thermal power or electricity.
The Mark-0 configuration was built specifically as a low-power physics test bed. It lacks the power conversion equipment, full heat removal systems, and balance-of-plant infrastructure that a commercial or higher-power prototype would require. This focused setup allowed Antares to complete the fueled test safely on an accelerated schedule; the company transitioned from chalkboard to splitting atoms in only nine months.
Criticality is the condition in which a nuclear reactor achieves a self-sustaining fission chain reaction. In practical terms, it means the number of neutrons produced by fission exactly balances the number lost to absorption or leakage. The reactor is neither increasing nor decreasing in power on its own; it holds steady at whatever level the operators set through control systems.
BWXT’s Fuel Role and the Supply Chain Connection BWXT played a direct, enabling role by manufacturing the fuel used in the Mark-0 test. The company also processed the HALEU feedstock into the form needed for advanced reactors. This work built on BWXT’s prior fuel production experience for the Army’s Project Pele microreactor program.
The successful use of this fuel in the first RPP criticality test highlights how established manufacturers reduce technical risk for newer reactor developers. BWXT’s Lynchburg facility has decades of specialized nuclear fuel fabrication expertise that newer entrants can leverage rather than recreate from scratch.
Aalo Atomics Positioned to Follow Quickly Aalo Atomics, also participating in the DOE RPP, is targeting its own criticality demonstration with the Aalo-X critical test reactor in the coming weeks, with the goal of meeting the July 4 executive order timeline. Aalo has already secured DOE approval to begin reactor start up preparations at INL.
Aalo maintains a strategic partnership with Flowserve (FLS) focused on pumps, valves, and critical flow-control equipment for its modular reactor designs aimed at data center applications. Flowserve’s involvement provides Aalo with proven nuclear-grade components and engineering support as it moves toward its own criticality milestone.
Implications for Investors and the Nuclear Value Chain Early criticality demonstrations like the one completed by Antares de-risk advanced reactor concepts and compress development timelines. They demonstrate today’s nuclear industry is ready, willing, and able to build capacity at speeds not seen since the 1950s/1960s.
The VettaFi Nuclear Renaissance Index (NUKZX) captures exposure to these developments through companies such as BWXT, which supplied the enabling fuel, and Flowserve, which is already partnered with the next company expected to reach criticality. NUKZX includes a diversified mix of fuel cycle, component, engineering, and service providers positioned across the nuclear value chain. NUKZX serves as the underlying index for the Range Nuclear Renaissance Index ETF (NUKZ).
These milestones illustrate how progress on advanced reactors creates tangible opportunities for established public companies long before any single reactor developer reaches commercial revenue. For investors seeking broad participation in the nuclear renaissance without concentrating risk in pre-revenue reactor developers, the diversified approach embedded in NUKZX offers a practical path to capture value from the full ecosystem supporting these projects.
Related Research: Investing in X-energy Without the Pre-Revenue IPO Risk
Today’s Energy Crisis & the Need for Nuclear Tomorrow
Not All Nuclear Exposure Is Created Equally
Looking for nuclear insights in your inbox? Subscribe here to keep a pulse on nuclear investing through our weekly research.
For more news, information, and analysis, visit the Nuclear Energy Content Hub.
vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for NUKZ, for which it receives an index licensing fee. However, NUKZ is not issued, sponsored, endorsed, or sold by VettaFi. VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of NUKZ.
The ongoing nuclear renaissance is entering an aggressive consolidation phase as public companies are snapping up private suppliers as they look to secure supply chains.
Key Takeaways Publicly traded nuclear energy companies are acquiring private supply chain companies to expand manufacturing depth and control deployment timelines. Industry players like BWX Technologies (BWXT), Nano Nuclear Energy (NNE), and Oklo (OKLO) have closed acquisitions to secure specialized engineering assets. The Range Nuclear Renaissance ETF (NUKZ) offers investors diversified exposure across this entire nuclear value chain. 3 Recent M&A Deals in the Nuclear Sector Three holdings in the Range Nuclear Renaissance ETF (NUKZ) have completed acquisitions of private supply chain companies to bolster their operations during the ongoing nuclear renaissance.
First, BWX Technologies (BWXT) has entered into a definitive agreement to acquire Precision Components Group (PCG). The strategic transaction adds more than 500,000 square feet of complex, heavy-walled and heat-transfer component capacity in the U.S. PCG generated approximately $125 million in revenue in 2025, providing BWXT with immediate commercial nuclear footprint expansion.
Next, Nano Nuclear Energy (NNE) has expanded its infrastructure footprint by acquiring Secured Transportation Services (STS). This acquisition ensures the microreactor developer controls the highly regulated logistics and transport mechanisms required for nuclear fuel and materials.
Finally, just this week, Oklo (OKLO) announced its acquisition of ARMEC, a precision manufacturing and mechanical engineering firm. The free-cash-flow-positive target company brings over two decades of operating experience in high-precision machining and prototyping. The integration directly aims to support faster design-to-manufacturing feedback for Oklo’s advanced reactor and fuel fabrication programs.
Capitalizing on the Value Chain via NUKZ The Range Nuclear Renaissance ETF (NUKZ) is designed to capture the entire nuclear value chain, incorporating multiple companies at every stage of the nuclear renaissance. This includes advanced reactor developers, utilities, construction services, as well as fuel suppliers. This allows investors to capture the secular growth of nuclear power while bypassing the complexity of managing foreign currency conversions or international brokerage accounts.
Looking for nuclear insights in your inbox? Subscribe here to keep a pulse on nuclear investing through our weekly research.
For more news, information, and analysis, visit the Nuclear Energy Content Hub.
vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for NUKZ, for which it receives an index licensing fee. However, NUKZ is not issued, sponsored, endorsed, or sold by VettaFi. VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of NUKZ.
June 15, 2026 06:29 ET | Source: Akamai Technologies, Inc.
Unified framework secures and scales interactions across the emerging AI-driven economyKnow Your Agent protocol verifies identity and human attribution by linking AI agents to authorized human usersReal-time decisioning layer connects identity and behavior to automate secure digital commerceDistributed edge enforcement protects performance while validating every automated requestEnhanced visibility allows organizations to distinguish, manage, and monetize agentic traffic
CAMBRIDGE, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- As AI agents increasingly act on behalf of users, every request raises critical questions of identity, intent, and trust. To address this, Akamai (NASDAQ: AKAM) today announced its unified agentic framework for its Bot & Agent Control solutions, which connects identity, observability, trust, and edge security into a single, real-time decisioning layer to power scalable AI-driven interactions at the edge.
Six tightly integrated pillars form the framework, which are delivered through a coordinated ecosystem of partners:
Verified identity and human attribution: Through its collaboration with Visa, Akamai is establishing a trusted foundation by authenticating AI agents for secure, permissioned transactions. Integrations with frameworks like Visa’s Trusted Agent Protocol are helping define how agents operate in payment environments, setting clearer standards for authorization, permissions, and transaction-level trust. Akamai is also collaborating with Skyfire and Experian to strengthen trusted AI agent identity through the “Know Your Agent” (KYA) framework, which provides a standardized way for agents to declare identity, origin, and intent, linking them to the platforms they operate on and the users they represent. KYA can help ensure that an AI agent is not only legitimate but is also verified as acting on behalf of a specific, authorized individual. This provides the accountability required for merchants to process automated transactions safely.“Without trusted identity and explicit permissioning, AI agents cannot participate in commerce at scale,” said Rubail Birwadker, SVP, Head of Growth Products and Partnerships, Visa. “Visa’s Trusted Agent Protocol provides the identity layer that defines how agents are authenticated, authorized, and trusted at the transaction level so businesses and consumers can transact with confidence.”
“AI agents are quickly becoming part of digital commerce, but trust will determine how far and how fast adoption grows,” said Kathleen Peters, Chief Innovation Officer at Experian. “With the Experian Agent Trust framework, we are helping businesses bring more transparency and accountability to AI-driven interactions by verifying identities, assessing risk, and strengthening confidence in every transaction. Our collaboration with Akamai and other ecosystem leaders reflects the industry’s shared commitment to building a secure foundation for agentic commerce that consumers and businesses can trust in real time.”
“AI agents can’t participate in the economy without trusted identity and the ability to transact,” said Amir Sarhangi, Co-Founder and CEO of Skyfire. “Skyfire provides that foundation — enabling agents to authenticate, operate within policy, and access global payment rails. With Akamai, we’re bringing that trust layer to the edge, so enterprises can securely enable trusted agents without re-architecting their existing systems.”
User-centric authentication: To maintain security during the handoff between a human and an AI agent, Akamai integrates with identity providers such as Auth0 and Ping Identity. These integrations allow businesses to apply existing security policies, such as behavioral analysis and multi-factor authentication, to the AI agents their customers use. This ensures that the agent’s actions remain consistent with the user’s established identity, behavior, and intent.“AI agents introduce a new trust challenge because session-based trust alone is no longer sufficient. Organizations need to understand who they represent, what agents are allowed to do, and how their actions are governed in real time,” said Loren Russon, SVP Product Management, Ping Identity. “By combining Ping’s runtime identity capabilities with Akamai’s edge enforcement and visibility, enterprises can extend identity and access controls to AI-driven interactions with stronger accountability and oversight.”
Adaptive trust analysis: The framework enables organizations to dynamically determine the trustworthiness and intent behind every interaction across browsers, bots, and agents. This shifts beyond binary decision-making toward a spectrum of trust that puts the user at the center, allowing customers to identify which interactions support business outcomes and which introduce abuse, fraud, or operational risk.Edge-based enforcement: Security and performance requirements for AI interactions are being met through Akamai’s distributed edge network. By utilizing high-performance compute, Akamai can evaluate the risk and intent of an agentic request instantly. Processing these decisions at the edge, Akamai helps businesses maintain security and control without compromising the speed of the user experience.Content monetization and value exchange: As AI models and agents consume more web content, the framework provides a path for fair compensation. Through partnerships with TollBit and Skyfire, Akamai enables publishers and content owners to negotiate access and facilitate tokenized, pay-per-request models. This allows businesses to monetize their data while providing AI agents with the licensed access they need to function.“AI agents are the new visitors and shoppers of the internet, and websites need a way to transact with them,” said Toshit Panigrahi, Co-Founder and CEO of TollBit. “By using Akamai’s ability to identify agentic traffic at the edge and redirect it to TollBit’s Agent Site, businesses can send agents to a dedicated, agent-optimized destination where they enforce their own access rules and turn it into a new revenue stream, making AI traffic a source of value rather than a cost.”
Operational visibility and traffic analysis: Through TrafficPeak and our industry-leading web security analytics, Akamai provides organizations with a unified view of their web traffic, distinguishing between human users, beneficial AI agents, and malicious bots. These high-scale log analyses allow security and business teams to observe how agents interact with their sites over time, providing the data necessary to refine access controls and commercial strategies. “AI agents are replacing clicks, acting and handling commerce for us. For that to work, businesses need to recognize not just the agent, but who is behind it and what it’s trying to do,” said Patrick Sullivan, VP, CTO of Security Strategy, Akamai. “We’ve built this so that identity informs visibility, visibility drives trust, and trust powers the decisions that let companies safely grow and monetize these new AI interactions. We’re giving businesses the confidence to open their doors to AI without compromising security.”
Across its ecosystem, Akamai is helping businesses move toward a unified approach to managing bots, agents, and users. The result is a scalable model where every interaction is verified, understood, and acted on in real time.
About Akamai
Akamai is the cybersecurity and cloud computing company that powers and protects business online. Our market-leading security solutions, superior threat intelligence, and global operations team provide defense in depth to safeguard enterprise data and applications everywhere. Akamai’s full-stack cloud computing solutions deliver performance and affordability on the world’s most distributed platform. Global enterprises trust Akamai to provide the industry-leading reliability, scale, and expertise they need to grow their business with confidence. Learn more at akamai.com and akamai.com/blog, or follow Akamai Technologies on X and LinkedIn.
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hub Group Inc. (NASDAQ:HUBG) for potential securities fraud after significant stock drops.
If you invested in Hub Group, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/hub-group-class-action-lawsuit.
Key Details of the Hub Group ($HUBG) Class Action Investigation:
Investigation Overview: Securities fraud regarding Hub Group’s financial restatements for the first nine months of 2025 and for the years ended December 31, 2024 and 2023 due to prematurely or incorrectly recognized transactions.Stock Declines: February 6, 2026 - 18% Stock DropMay 12, 2026 - 13% Stock Drop Action: Contact BFA Law to discuss your rights
Why is Hub Group Being Investigated for Securities Fraud?
Hub Group is a supply chain solutions provider that offers transportation and logistics management services. Hub Group is one of the largest freight transportation providers in North America.
BFA is investigating Hub Group’s financial statements for the first nine months of 2025 and for the years ended December 31, 2024 and 2023, due to prematurely or incorrectly recognized transactions.
Why did Hub Group’s Stock Drop?
On February 5, 2026, Hub Group announced that it would delay the full release of its fourth quarter and full year 2025 financial results and will restate its financial statements for the first three quarters of 2025 due to an error that understated purchased transportation costs and accounts payable.
This news caused the price of Hub Group stock to decline $9.37 per share, or 18%, from a closing price of $51.33 per share on February 5, 2026, to $41.96 per share on February 6, 2026.
Then, on May 12, 2026, Hub Group announced that its previously issued audited financial statements for the years ended December 31, 2024 and 2023 were materially misstated and should no longer be relied upon. Hub Group stated that it identified premature or incorrectly recognized transactions and that it expects to conclude that it did not maintain effective disclosure controls and internal control over financial reporting for the years ended December 31, 2024 and 2023.
This news caused the price of Hub Group stock to decline $5.24 per share, or 13%, from a closing price of $41.86 per share on May 11, 2026, to $36.62 per share on May 12, 2026.
Click here for more information: https://www.bfalaw.com/cases/hub-group-class-action-lawsuit.
What Can You Do?
If you invested in Hub Group, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
VANCOUVER, British Columbia, June 15, 2026 (GLOBE NEWSWIRE) -- Anfield Energy Inc. (NASDAQ: AEC; TSX.V: AEC; FRANKFURT: 0AD) (“Anfield” or the “Company”) is pleased to announce a key milestone in its equipment procurement program. The Company has received the first custom-built underground haul truck off the Young’s Machine Company (“Young’s”) production line, following its 2025 order for specialized mining equipment.
Anfield representatives visited the Young’s facility in Monticello, Utah, and were present in person to receive the first truck off the production line. This delivery marks an integral step forward as Anfield advances toward production. The new truck is currently slated for operation at the Velvet-Wood uranium-vanadium mine in southeastern Utah. Later in the year, it will be relocated to the Company’s Colorado mines once the larger underground haul trucks are completed and delivered.
Corey Dias, CEO of Anfield, commented: “Receiving the first truck off the production line is an important milestone which underscores our strong partnership with a proven local Utah manufacturer and our shared commitment to building a robust American supply chain for domestic uranium production. Young’s Machine Company’s long-standing expertise in serving the Western mining sector makes it an ideal partner as we ramp up production not only at Velvet-Wood, JD-8 and Slick Rock, but also across our other mines as part of our hub-and-spoke model.”
A representative from Young’s Machine Company added: “Anfield’s important work is key to securing U.S. energy independence. Delivering this first unit on schedule highlights our capability to produce high-quality, custom underground mining equipment right here in Utah’s mining heartland.”
Additionally, Anfield has reached a further agreement with Young’s, under which Young’s will supply underground loaders to support Anfield’s mining operations across its projects. This underground equipment will be enough to support initial development and production from Anfield’s operations at Velvet-Wood, JD-8, and Slick Rock.
About Young’s Machine Company
Young’s Machine Company is a third-generation, family-owned manufacturer based in Monticello, Utah, that has been producing custom underground haul trucks and specialized mining equipment since 1953 — spanning over 70 years of service to the Western U.S. mining industry. Located in the heart of Utah’s historic uranium mining region on the Colorado Plateau, Young’s has built a strong reputation for “mine-tested” equipment tailored to the rugged demands of underground operations in the American West. This partnership reinforces Anfield’s commitment to local supply chains and domestic manufacturing in support of U.S. uranium production.
About Anfield
Anfield is a uranium and vanadium development company that is committed to becoming a top-tier energy-related fuels supplier by creating value through sustainable, efficient growth in its assets. Anfield is a publicly traded corporation listed on the NASDAQ (AEC-Q), the TSXV (AEC-V) and the Frankfurt Stock Exchange (0AD).
Career Opportunities
As Anfield Energy continues to expand its U.S. operations amid strong momentum in the domestic nuclear sector, the Company is actively attracting and hiring top talent in mining, milling, and related technical fields. Interested candidates are encouraged to visit the Anfield Energy website at www.anfieldenergy.com for current job openings and career opportunities.
On behalf of the Board of Directors
ANFIELD ENERGY INC.
Corey Dias, Chief Executive Officer
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Anfield Energy, Inc.
Corporate Communications
604-669-5762 [email protected]
www.anfieldenergy.com
This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical facts, are forward-looking statements. Generally, forward-looking statements can be identified by the use of terminology such as “seek”, “expect”, “anticipate”, “budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”, “predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will” and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved” (including negative variations). Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s business plans, objectives and strategies of operations, including, without limitation, the Company’s refurbishment and reactivation plans for Shootaring and the Company’s plans for advancing its Velvet-Wood, JD-8 and Slick Rock mines. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance and opportunities to differ materially from those implied by such forward looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, among other things: risk related to the Company’s refurbishment and reactivation plans for Shootaring; risks related to the plans for advancing its Velvet-Wood, JD-8 and Slick Rock mines; the risks and uncertainties relating to exploration and development; the ability of the Company to obtain additional financing; the need to comply with environmental and governmental regulations in Canada and the United States; fluctuations in the prices of commodities; operating hazards and risks; competition and other risks and uncertainties and other such factors as are set forth in the annual information form for the Company’s most recently completed year end, as well as the management discussion and analysis and other disclosures of risk factors for the Company, filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the information and assumptions used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
GRAND FALLS-WINDSOR, Newfoundland and Labrador, June 15, 2026 (GLOBE NEWSWIRE) -- First Atlantic Nickel & Cobalt Corp. (TSXV: FAN | OTCQB: FANCF | FSE: P21) (the “Company” or “First Atlantic”) is pleased to announce the visual results of the first drill hole at the Alloy Max Zone, the Company’s second large-scale awaruite (Ni₃Fe) nickel-cobalt alloy discovery. The Alloy Max Zone is located approximately 7 km north of the discovery at the RPM Zone within the 30 km Pipestone Ophiolite Complex at the Company’s Pipestone XL Nickel-Cobalt Alloy Project in central Newfoundland.
The first hole at Alloy Max North, XL-26-15, intersected visibly disseminated awaruite over its entire 414-meter length and ended in mineralization, with visual abundance and grain size increasing down hole toward the east. The visual identification of disseminated awaruite indicates the potential for a second large area of mineralization within the Pipestone XL project in addition to the RPM Zone.
Drilling is ongoing at Alloy Max North and South, with additional drill holes underway from additional drill pads. At each location, Company’s geologists identified visible awaruite in exposed bedrock prior to drilling, providing further support for the surface expression of awaruite mineralization across the zone.
KEY HIGHLIGHTS
First Drill Hole Confirms a Second Large-Scale Discovery: XL-26-15, the first hole drilled at Alloy Max North, establishes a new mineralized area approximately 5.2 km north of the RPM Zone discovery hole AN-24-02. The visual identification of disseminated awaruite indicates the potential for a second large area of mineralization within the Pipestone XL project in addition to the RPM Zone.Visible Awaruite Over the Entire 414-Meter Drill Hole: Drilled at a 60-degree dip to the east, XL-26-15 intersected visibly disseminated awaruite throughout its 414-meter length and ended in open mineralization, with visual abundance and grain size increasing down hole.Only 200 m of Lateral Width of 1.5 km Drill-Tested: XL-26-15 tested approximately 200 meters of width within a zone mapped roughly 1.5 km wide, leaving approximately 1.3 km of untested width to the east, where mineralization visually improves down hole.4 km Strike Length, Significantly Larger Than the RPM Zone: Alloy Max spans approximately 4 km of strike and is significantly larger than the RPM Zone in both strike length and width (area), defined by geological mapping, geophysics and surface Davis Tube Recovery (“DTR”) sampling.Significantly Larger Target Footprint Than the RPM Zone: As outlined in the Company’s March 18 and April 8, 2026 news releases, Alloy Max represents a significantly larger target than the RPM Zone. The Company now believes the Alloy Max Zone could measure up to 1.5 km in width and 4 km in strike length. At the RPM Zone, drill-core DTR grades returned significantly higher magnetically recoverable nickel than average surface samples collected from the same area.Drilling to Test Open Mineralization to the East: Further drilling at Alloy Max North will step east into the larger mineralized area, where mineralization improved with depth in XL-26-15.Visible Awaruite Identified in Surface Bedrock Before Drilling: Minimal overburden allowed Company geologists to expose and directly sample bedrock at Alloy Max North and South, where visible awaruite was identified at additional drill pad locations before drilling. For investor inquiries or questions, please call Rob Guzman, Investor Relations, at +1-844-592-6337 or email [email protected].
The Company's new white paper, Onshoring the Nickel-Cobalt Supply Chain. Without a Smelter, released on June 9, 2026, is available now at www.fanickel.com.
DISCOVERY HOLE XL-26-15: 414 METERS OF VISIBLE AWARUITE AT ALLOY MAX NORTH
XL-26-15 is the first drill hole completed at Alloy Max North and the discovery hole for the Alloy Max Zone, a new large-scale awaruite zone located approximately 5.2 km north of the Company’s RPM Zone discovery hole, AN-24-02. Drilled at a 60-degree dip to the east, XL-26-15 intersected visibly disseminated awaruite over its entire 414-meter length and ended in open mineralization. Visual abundance and grain size increased down hole toward the east, indicating that the system strengthens in that direction and remains open for expansion.
The hole tested only a narrow slice of the zone, covering approximately 200 meters of width against a mapped width of roughly 1.5 km and leaving the large majority of the approximately 4 km strike length undrilled. Drilling is now continuing in the Alloy Max Zone across additional drill pads, where minimal overburden has allowed Company geologists to expose and sample bedrock directly and identify visible awaruite prior to drilling, consistent with the surface sampling results reported on March 18, 2026.
Much of this ground had seen little historical exploration, with prior operators not testing specifically for awaruite or conducting DTR analysis. Improved road access and drier ground conditions have allowed the Company to access the Alloy Max area where drilling is ongoing.
Alloy Max North has the potential to be represent a new, larger area of disseminated awaruite mineralization in addition to the RPM Zone, in line with the Company’s mission to develop a multi-deposit nickel-cobalt alloy mining district with centralized onshore processing feeding directly into downstream industries, bypassing midstream smelting constraints in North America.
THE ALLOY MAX ZONE: A SECOND LARGE-SCALE AWARUITE DISCOVERY
The Alloy Max Zone was first announced on March 18, 2026, following district-wide surface sampling that integrates field geological mapping, surface rock sampling with DTR analysis, and geophysics. This work outlined a major new area of magnetically recoverable awaruite mineralization up to approximately 7 km north of the RPM Zone. The initial target area measures approximately 4 km in length and 1.5 km in width, with geophysical processing indicating the potential for a mineralized area larger than the RPM Zone.
Surface DTR sampling at Alloy Max has returned magnetically recoverable nickel grades comparable to surface values at the RPM Zone, where drill core has consistently returned significantly higher DTR grades than weathered surface samples. This established relationship between surface and drill-core grades forms the basis for the Company’s expectation of higher grades at depth, and was a factor in Alloy Max being selected as a priority drill target for 2026.
The Pipestone Ophiolite Complex is a major belt of ultramafic rocks emplaced along a continental-scale fault system. The Company believes Alloy Max is related to this major tectonic event, which would have supplied the large volumes of heat and fluid required to form awaruite. Awaruite forms during serpentinization, when ultramafic rock reacts with water, interpreted here to have been sourced from ocean water, generating the large volumes of molecular hydrogen (H₂) needed to reduce nickel to its native metallic alloy state. A regional, crustal-scale fault structure cuts the 30 km Pipestone XL Ophiolite Complex, providing the pathway for fluids to interact with the host rock, generate hydrogen, and reduce nickel to metal across the trend.
AWARUITE CONFIRMED AT THE RPM ZONE: 77.62% NICKEL, 1.69% COBALT
On May 21, 2026, the Company confirmed awaruite at the RPM Zone through electron microprobe analysis by SGS Canada Inc., which averaged 77.62% nickel and 1.69% cobalt.
These results confirm the high-grade, naturally magnetic nickel-iron-cobalt (Ni-Fe-Co) alloy at Pipestone XL, a metallic mineralogy that can be concentrated through magnetic separation and flotation and processed onshore directly into downstream nickel and cobalt products, bypassing conventional smelting, roasting and high-pressure acid leaching.
GEOLOGIC HYDROGEN AND THE VEMA HYDROGEN JOINT VENTURE
The same serpentinization process associated with awaruite formation at Pipestone XL also generates hydrogen, and the Company is advancing a parallel geologic hydrogen initiative alongside its nickel-cobalt program. As announced on June 9, 2026, First Atlantic and Vema Hydrogen signed a letter of intent to jointly develop low-carbon Engineered Mineral Hydrogen (EMH) at Pipestone XL through a proposed 50/50 joint venture. The presence of awaruite, which forms only when hydrogen reduces nickel and iron during serpentinization, is a direct geological signature of a hydrogen-generating system.
Samples from the Alloy Max Zone, including drill core from XL-26-15 and subsequent holes, will be used in the Company’s Engineered Mineral Hydrogen (EMH) evaluation work at Pipestone XL.
Figure 1. Visible Awaruite Grains up to 382 microns in drill hole XL-26-15 at 340 Meters, Alloy Max North.
Figure 2. Visible Awaruite Grains up to 160 microns in drill hole XL-26-15 at 256 Meters, Alloy Max North.
Figure 3. Visible Awaruite Grains up to 298 microns in drill hole XL-26-15 at 106 Meters, Alloy Max North.
Figure 4. Map of the Alloy Max and RPM Zone areas showing DTR nickel (%) in surface rock samples, including 2026 Alloy Max drill pad locations and the RPM 2025 drill holes.
AWARUITE: A SMELTER-FREE NICKEL-COBALT ALLOY (Ni₃Fe)
Figure 5: USGS quote on awaruite nickel-iron-cobalt alloy.
Awaruite is a naturally occurring, sulfur-free nickel-iron-cobalt alloy with nickel content of approximately 77%. Because it already exists in a metallic state, awaruite can be processed into a high-grade concentrate of approximately 60% nickel through magnetic separation and flotation, without smelting, roasting, or high-pressure acid leaching. This concentrate can be sent directly for downstream battery chemical refining or for the manufacture of specialty alloys and stainless steel.
As stated in the August 2025 report From Rocks to Power: Strategies to Unlock Canada’s Critical Minerals for Global Leadership in Energy Storage, EVs, & Beyond from the Battery Metals Association of Canada:
“Awaruite is not a sulfide nor an oxide nickel ore but a high-content native nickel-iron ore. Simple beneficiation processes after mining could provide 60% Ni concentrate, ready for leaching for battery cathode purposes and would yield MHP as a by-product. This process would bypass pyrometallurgy or early hydrometallurgy stages and be among the lowest carbon-intensive nickel production sites in the global nickel market.”1
The U.S. Geological Survey highlighted awaruite’s potential in its Mineral Commodity Summaries 2012, stating:
“The development of awaruite deposits in other parts of Canada may help alleviate any prolonged shortage of nickel concentrate. Awaruite, a natural iron-nickel alloy, is much easier to concentrate than pentlandite, the principal sulfide of nickel.”2
The absence of sulfur reduces the risk of acid mine drainage and certain permitting challenges commonly associated with sulfide mineralization, positioning awaruite to supply North American industries including stainless steel, electric vehicles, aerospace, and defence.
INVESTOR INFORMATION
The Company’s common shares trade on the TSX Venture Exchange under the symbol “FAN”, the American OTCQB Exchange under the symbol “FANCF” and on several German exchanges, including Frankfurt and Tradegate, under the symbol “P21”.
Investors can get updates about First Atlantic by signing up to receive news via email and SMS text at www.fanickel.com.
Adrian Smith, P.Geo., a director and the Chief Executive Officer of the Company is a qualified person as defined by NI 43-101. The qualified person is a member in good standing of the Professional Engineers and Geoscientists Newfoundland and Labrador (PEGNL) and is a registered professional geoscientist (P.Geo.). Mr. Smith has reviewed and approved the technical information disclosed herein.
About First Atlantic Nickel & Cobalt Corp.
First Atlantic Nickel & Cobalt Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) is a critical mineral exploration company in Newfoundland & Labrador developing the Pipestone XL Nickel-Cobalt Alloy Project. The project spans the entire 30-kilometer Pipestone Ophiolite Complex, where multiple zones, including RPM, Alloy Max, Super Gulp, Atlantic Lake, and Chrome Pond, contain awaruite (Ni₃Fe), a naturally occurring magnetic nickel-iron-cobalt alloy of approximately ~77% nickel with no sulfur and no sulfides, along with secondary chromium mineralization. Awaruite’s sulfur-free composition removes acid mine drainage (AMD) risks, while its unique magnetic properties enable processing through magnetic separation, eliminating the electricity requirements, emissions, and environmental impacts of conventional smelting, roasting, or high-pressure acid leaching while reducing dependence on overseas nickel processing infrastructure.
The U.S. Geological Survey recognized awaruite’s strategic importance in its 2012 Annual Report on Nickel, noting that these deposits may help alleviate prolonged nickel concentrate shortages since the natural alloy is much easier to concentrate than typical nickel sulfides. The Pipestone XL Nickel-Cobalt Alloy Project is located near existing infrastructure with year-round road access and proximity to hydroelectric power. These features provide favorable logistics for exploration and future development, strengthening First Atlantic’s role to establish a secure and reliable source of North American nickel production for the stainless steel, electric vehicle, aerospace, and defense industries. This mission gained importance when the U.S. added nickel to its critical minerals list in 2022, recognizing it as a non-fuel mineral essential to economic and national security with a supply chain vulnerable to disruption.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are frequently identified by words such as "expects", "intends", "plans", "anticipates", "believes", "may", "will", "would", "could", "potential", "proposed", "target", "prospective", "indicates", "designed to", "expected to" and similar expressions, or statements that events, conditions or results "will", "may", "could", "would" or "should" occur or be achieved.
Forward-looking information in this news release includes, but is not limited to, statements regarding the Company’s exploration plans, results, expectations and objectives at the Pipestone XL Nickel-Cobalt Alloy Project; the interpretation of visual mineralization, awaruite abundance and grain size observed in drill core; the potential scale, continuity, geometry, width, strike length and expansion potential of the Alloy Max Zone; the potential for Alloy Max to represent a second large-scale mineralized zone or discovery in addition to the RPM Zone; the potential for the Pipestone XL Project to host multiple deposits or support a future nickel-cobalt mining district; the future of onshore processing; the expectation that mineralization may continue or improve to the east or at depth; the Company’s plans for additional drilling at Alloy Max North, Alloy Max South, RPM and elsewhere within the Pipestone Ophiolite Complex; the expectation that drill-core DTR grades may be higher than surface sample grades; the geological interpretation of the Pipestone Ophiolite Complex, including the role of serpentinization, regional structures, fluids, hydrogen generation and awaruite formation; the Company’s plans to evaluate geologic hydrogen potential; the proposed joint venture with Vema Hydrogen and the potential development of low-carbon EMH; and the potential use of samples from Alloy Max, RPM and other areas for future hydrogen evaluation work.
Forward-looking information is based on a number of assumptions that management considers reasonable as of the date of this news release, including assumptions regarding the accuracy of visual observations, geological mapping, geophysical interpretations, DTR sampling and other exploration data; the continuity and geometry of mineralization; the relationship between surface sampling and drill-core results; the Company’s ability to complete planned drilling, sampling, assaying, metallurgical, hydrogen and other technical work; the availability of financing, equipment, personnel, contractors, permits and road access; the continued validity of the Company’s geological model; the ability of the Company and Vema Hydrogen to negotiate, finalize and implement definitive joint venture arrangements; and general business, market, commodity price and regulatory conditions.
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, risks associated with early-stage mineral exploration; the risk that visual observations of mineralization may not correlate with assay results, DTR results, recoverability, grade, tonnage or economic viability; the risk that future drilling may not confirm the expected continuity, scale, grade, width or depth extent of mineralization; the risk that surface sampling, geophysical data and geological interpretations may not accurately predict subsurface mineralization; uncertainty regarding metallurgical recoverability and processing characteristics; uncertainty regarding the potential generation, recovery, storage, commerciality or development of geologic hydrogen; risks relating to the negotiation and completion of definitive agreements with Vema Hydrogen; permitting, environmental, access, title, regulatory and community-related risks; the availability of capital and financing on acceptable terms; changes in commodity prices, market conditions and investor sentiment; operational risks; weather and seasonal access limitations; and the other risks described in the Company’s public disclosure documents.
The Company is an exploration-stage issuer and has not established mineral resources or mineral reserves at the Pipestone XL Nickel-Cobalt Alloy Project. There can be no assurance that further exploration or technical work will result in the delineation of mineral resources or mineral reserves, or that the project will be advanced to production. Readers should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is made as of the date of this news release, and the Company undertakes no obligation to update or revise such information except as required by applicable law.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/76c3c075-4da1-4a06-9248-f5b7a2335cb0
https://www.globenewswire.com/NewsRoom/AttachmentNg/acfe3c10-00df-4f52-a5c2-9d266ee27a91
https://www.globenewswire.com/NewsRoom/AttachmentNg/7e3a1a28-ca0e-4e7c-9123-80df309de5da
https://www.globenewswire.com/NewsRoom/AttachmentNg/221f6c2e-2cbf-4f38-a7bd-a0aacc52522c
https://www.globenewswire.com/NewsRoom/AttachmentNg/7509daf3-3322-499d-9142-2b4f05f9de61
First Advantage (FA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Recognized for advancing intelligent microgrid systems that enhance energy resilience, support decarbonization, and ensure operational continuity
, /PRNewswire/ -- Frost & Sullivan is pleased to announce that Ameresco has received the 2026 North America Technology Innovation Leadership Recognition in the Microgrid sector. Frost & Sullivan recognized Ameresco for its ability to design, deploy, and operate advanced microgrid systems that integrate distributed energy resources, energy storage, and intelligent controls to improve energy resilience, support decarbonization, and ensure operational continuity across mission-critical applications. This recognition highlights Ameresco's consistent leadership in driving measurable outcomes, strengthening its market position, and delivering customer-centric innovation in an evolving competitive landscape.
Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Ameresco excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale. "Building on this technological foundation, Ameresco develops and deploys advanced microgrid systems that function as intelligent energy platforms. Through integrated control architectures, real-time monitoring, and lifecycle optimization, these systems dynamically manage energy flows, enhance system reliability, and reduce dependence on centralized infrastructure," said Chippy Alphons Augustine, Research Analyst at Frost & Sullivan.
Guided by a long-term strategy focused on energy resilience, distributed energy infrastructure, and customer-centric project delivery, Ameresco has successfully expanded its microgrid footprint across federal, municipal, utility, and commercial markets. The company's continued investment in advanced microgrid technologies and integrated energy solutions has enabled it to scale deployments across North America while addressing evolving customer requirements for reliability, energy security, and sustainability.
Technology leadership remains central to Ameresco's approach. Its suite of integrated microgrid solutions addresses the full spectrum of modern energy needs, offering flexibility, scalability, and high-performance energy optimization. Ameresco's technology-agnostic approach enables the integration of renewable generation, energy storage, and dispatchable energy resources into site-specific microgrid configurations tailored to customer operational requirements.
"We're honored to be recognized by Frost & Sullivan for our leadership in microgrid innovation," said Nicole Bulgarino, Co-President of Ameresco. "We believe the future of power must be more resilient, intelligent, and adaptable, and we remain committed to helping our customers modernize their energy infrastructure in ways that strengthen reliability, support sustainability, and create lasting value."
Ameresco's unwavering commitment to customer experience further strengthens its position in the market. Its integrated delivery model combines project development, financing, engineering, construction, and long-term operations, enabling customers to realize value throughout the project lifecycle. Through real-time system visibility, operational oversight, and high levels of system performance, the company continues to meet the needs of its expanding customer base. The company's deployment portfolio spans federal agencies, municipalities, utilities, and commercial customers, including mission-critical environments where reliability and energy security are essential. Its technology-agnostic approach and focus on localized, mission-critical deployments have been key to delivering long-term value across diverse sectors.
Frost & Sullivan commends Ameresco for setting a high standard in competitive strategy, execution, and market responsiveness. The company's ability to combine technology innovation, disciplined execution, and long-term operational expertise is helping advance resilient energy infrastructure solutions that address the evolving needs of modern power systems.
Each year, Frost & Sullivan presents the Technology Innovation Leadership to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition identifies forward-thinking organizations that are reshaping their industries through innovation and growth excellence.
Frost & Sullivan Best Practices Recognition
Frost & Sullivan's Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.
Contact:
Ashley Shreve
E: [email protected]
Media Contact:
Ameresco: Leila Dillon, 508-661-2264, [email protected]
About Ameresco, Inc.
Founded in 2000, Ameresco, Inc. (NYSE:AMRC) is a leading energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the global energy transition. Our comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. As a trusted full-service partner, Ameresco shows the way by reducing energy use and delivering energy infrastructure solutions to Federal, state and local governments, utilities, data centers, educational and healthcare institutions, housing authorities, and commercial and industrial customers. Headquartered in Framingham, MA, Ameresco has more than 1,500 employees providing local expertise in North America and Europe. For more information, visit www.ameresco.com.
LOS ANGELES, June 15, 2026 /PRNewswire/ -- BRC Group Holdings, Inc. (Nasdaq: RILY) ("BRC" or the "Company") today provided supplemental information regarding its indirect economic interest in Space Exploration Technologies Corp. ("SpaceX"), following SpaceX's initial public offering on June 12, 2026 (the "IPO"). The Company discussed this interest in its latest filing on Form 10-Q for the quarterly period ended March 31, 2026 filed on May 7, 2026 and its most recent quarterly earnings call on May 7, 2026.
According to recent news, Constellation Energy announced on June 1 an underwritten public offering of 11 million shares.
ManpowerGroup Inc. (NYSE:MAN) has “never really been a great win” for him, Cramer said.
On April 30, ManpowerGroup announced the sale of its Jefferson Wells U.S. business to Sikich for a transaction value of $100 million.
Cramer recommended holding on to Credo Technology Group Holding Ltd (NASDAQ:CRDO), adding that it is “just so good.”
On the earnings front, Credo Technology Group, on June 1, posted fourth-quarter revenue of $437 million, beating analyst estimates of $432.05 million. The connectivity solutions company reported adjusted earnings of $1.16 per share for the quarter, beating analyst estimates of $1.03 per share, according to Benzinga Pro.
Cramer said he doesn't want Perrigo Company plc (NYSE:PRGO), adding that it's a “value trap” and doesn't have any growth.
According to recent news, Perrigo appointed Albert A. Manzone as interim president and CEO on June 8, succeeding Patrick Lockwood-Taylor.
Cadence Design Systems, Inc. (NASDAQ:CDNS) is a “hold, and if it comes down it's a buy,” Cramer said.
On June 9, Stifel analyst Ruben Roy maintained Cadence Design Systems with a Buy rating and raised the price target from $395 to $432.
Price Action:
Constellation Energy shares gained 2.9% to settle at $253.76 on Friday. Credo Technology shares fell 5.3% to close at $250.81. ManpowerGroup shares closed at $34.00 on Friday. Perrigo shares rose 0.8% to settle at $10.99. Cadence Design shares gained 0.3% to close at $384.96 on Friday. Photo: Shutterstock edited by Benzinga
Market News and Data brought to you by Benzinga APIs
Will create a bank holding company with approximately $2.4 billion in assets and 10 branches across Washington, D.C., Virginia, Maryland, Pennsylvania, and Florida
Will be the 7th largest bank headquartered in the Washington, D.C. MSA
Greater scale and resources to deliver best-in-class products and services
Like-minded institutions with strong cultural alignment and a longstanding commitment to employees, customers, shareholders, and the communities they serve
Both companies operate on the same data processing system, which is expected to facilitate the operational integration with little disruption to customers
Significant EPS accretion
Attractive, low-cost core funding base
Opportunity for meaningful value creation for shareholders with strong pro forma profitability
Anticipated listing on Nasdaq or the NYSE concurrent with the merger closing
Expected increased trading liquidity for both companies and continuation of the equivalent of NACB's current dividend
, /PRNewswire/ -- ODNB Financial Corporation (private) ("ODNB"), the holding company of Old Dominion National Bank, and National Capital Bancorp, Inc. (OTCID: NACB) ("NACB"), the holding company of The National Capital Bank of Washington ("National Capital Bank"), today jointly announced they have entered into a definitive merger agreement pursuant to which NACB will merge into ODNB, with ODNB surviving as the bank holding company. The combined holding company, which will be named National Capital Bancorp, Inc., expects to list its common stock on Nasdaq or the New York Stock Exchange and trade under the ticker symbol "NACB". Old Dominion National Bank will merge with and into National Capital Bank, with National Capital Bank surviving as the wholly owned subsidiary bank. In Pennsylvania, Centre 1st Bank will continue as a division of the combined bank. Richard B. (Randy) Anderson, Jr., current Chairman and CEO of NACB, will serve as non-executive Chairman of the Boards of the combined holding company and combined bank. Mark Merrill, current Chairman and CEO of ODNB, will serve as CEO of the combined holding company and bank. He will also serve as the President of the combined bank. Jack Infield, current President of ODNB, will serve as President of the combined holding company. The combined company's board of directors will have seventeen directors, consisting of ten directors from ODNB and seven directors from NACB.
Mark Merrill commented, "This strategic combination creates a strong and promising future for our organization, our customers, and our shareholders. NACB brings one of the strongest deposit bases in the Washington, D.C. region, which complements ODNB's best-in-class growth rate. I am also very pleased that Randy Anderson will serve as Chairman of the combined company and bank. Randy and I have known each other for more than a dozen years and have worked together in the past. We share the same philosophy and values, and we believe that bringing our teams together as one company will be a meaningful step forward for both organizations. I am excited to lead a talented management team focused on delivering exceptional customer service, increasing shareholder value, and continuing our commitment to the communities we serve."
Randy Anderson added, "ODNB and NACB are community-focused organizations with similar cultures and a shared commitment to customers. This merger brings together two strong teams dedicated to exceptional client service, lasting relationships, and helping individuals and businesses achieve their financial goals. The combined bank will remain committed to the relationships we have built over many decades of service to our communities. With greater scale, expanded resources, higher loan limits, and broader geographic reach, we will be better positioned to serve customers, support employees with additional career opportunities, deepen our presence in existing markets, and expand more effectively into the markets we seek to serve. We are honored to partner with Mark and his team."
Transaction Details
Under the terms of the definitive merger agreement, which was unanimously approved by the boards of directors of both companies, holders of NACB common stock will have the right to elect to receive: (a) 100% stock at an exchange ratio of 5.2390 shares of common stock of ODNB for each share of NACB, (b) 100% cash at $83.00 per share, or (c) a mixture of 90% stock and 10% cash. The cash portion of the merger consideration will not exceed 10% of the total merger consideration, will not exceed $1.0 million (12,048 shares) per NACB shareholder, and will be subject to certain proration procedures. Existing ODNB shareholders are expected to own approximately 65%-68% of the outstanding shares of the combined company and NACB shareholders are expected to own approximately 32%-35%, based upon the outcome of the election process.
At March 31, 2026, ODNB valued its common stock at $16.24 per share. Assuming that the election procedures result in the merger consideration being 90% stock and 10% cash, the transaction is expected to be over 50% accretive to earnings per share ("EPS") in 2027. The combined company is expected to have total assets of approximately $2.4 billion on a pro forma basis at closing.
Timing and Approvals
The merger is expected to close in the fourth quarter of 2026, subject to satisfaction of customary closing conditions, including regulatory approvals and shareholder approvals from ODNB and NACB shareholders. ODNB and NACB directors have entered into agreements pursuant to which they have committed to vote their shares of ODNB and NACB common stock, respectively, in favor of the merger.
Advisors
Piper Sandler & Co. acted as financial advisor to NACB and delivered a fairness opinion to the Board of Directors of NACB, and Williams Mullen served as legal counsel to NACB. D.A. Davidson & Co. acted as financial advisor to ODNB in the transaction and delivered a fairness opinion to the Board of Directors of ODNB. Troutman Pepper Locke LLP served as legal counsel to ODNB.
About ODNB Financial Corporation
ODNB Financial Corporation is the holding company for Old Dominion National Bank, a locally owned community bank serving markets including the Washington, D.C. metropolitan area. The Bank's executive headquarters is located in the heart of Northern Virginia in Tysons Corner, with full-service branches in Tysons Corner and Leesburg, Virginia, as well as communities in Central Virginia through its Albemarle County branches and in South Florida through its Boca Raton office.
Centre 1st Bank, a wholly owned division of Old Dominion National Bank, serves customers in Pennsylvania and New Jersey from offices in State College, Pennsylvania.
ODNB offers clients with a full spectrum of financial services, ensuring access to top-tier technology and personalized solutions to help achieve their financial goals. ODNB had $1.6 billion in total assets at March 31, 2026. For more information about ODNB, visit www.odnb.bank.
About National Capital Bancorp, Inc.
National Capital Bancorp, Inc. is the holding company for The National Capital Bank of Washington, which was founded in 1889 and is Washington's Oldest Bank. NACB is headquartered on Capitol Hill with offices in the Friendship Heights community in Northwest, D.C., the Courthouse/Clarendon community in Arlington, Virginia and the Fox Hill senior living community of Bethesda, Maryland. National Capital Bank also operates residential mortgage and commercial lending offices and a wealth management services division. National Capital Bank product and service offerings include personal and business deposit accounts, robust online and mobile banking services and sophisticated treasury management solutions – all delivered with top-rated personal service. National Capital Bank is well positioned to serve all the banking needs of those in our communities. NACB had $735.3 million in total assets at March 31, 2026. For more information about NACB, visit www.nationalcapitalbank.bank.
This communication includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts, but instead represent only the beliefs, expectations, or opinions of ODNB and NACB and their respective management teams regarding future events, many of which, by their nature, are inherently uncertain and beyond the control of ODNB and NACB. Forward-looking statements may be identified by the use of such words as: "believe," "expect," "anticipate," "intend," "plan," "estimate," or words of similar meaning, or future or conditional terms, such as "will," "would," "should," "could," "may," "likely," "probably," or "possibly." These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management, including Mark Merrill's and Randy Anderson's quotations and statements about (i) the benefits of the proposed transaction, including future financial and operating results, costs savings, enhancement to revenue and accretion to reported earnings that may be realized from the proposed transaction; (ii) the expected timing of completion of the proposed transaction; and (iii) ODNB's and NACB's plans, objectives, expectations and intentions and other statements contained in this communication that are not historical facts. In addition, these forward-looking statements are subject to various risks, uncertainties, estimates, and assumptions with respect to future business strategies and decisions that are subject to change and difficult to predict with regard to timing, extent, likelihood and degree of occurrence. Although ODNB's and NACB's respective management teams believe that estimates and assumptions on which forward-looking statements are based are reasonable, such estimates and assumptions are inherently uncertain. As a result, actual results may differ materially from the anticipated results discussed in these forward-looking statements as a result of a variety of factors, many of which are beyond the control of ODNB and NACB.
The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) the business of NACB may not be successfully integrated into ODNB or the business of Old Dominion National Bank may not be successfully integrated into National Capital Bank, or such integration may take longer, be more difficult, time-consuming or costly to accomplish than expected; (2) the expected growth opportunities or cost savings from the proposed transaction may not be fully realized or may take longer to realize than expected; (3) deposit attrition, operating costs, customer losses and business disruption following the proposed transaction, including adverse effects on relationships with employees and customers, may be greater than expected; (4) the possibility that the proposed transaction does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all, or are obtained subject to conditions that are not anticipated (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the proposed transaction); (5) the outcome of any legal proceedings that may be instituted against ODNB or NACB; (6) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement between ODNB and NACB; (7) reputational risk and potential adverse reactions of ODNB's or NACB's customers, employees or other business partners, including those resulting from the announcement or completion of the proposed transaction; (8) the dilution caused by ODNB's issuance of additional shares of its capital stock in connection with the proposed transaction; (9) the diversion of management's attention and time from ongoing business operations and opportunities on merger-related matters; (10) certain restrictions during the pendency of the proposed transaction that may impact the parties' ability to pursue certain business opportunities or strategic transactions; (11) economic, legislative or regulatory changes, including changes in accounting standards, may adversely affect the businesses in which ODNB and NACB are engaged; (12) competitive pressures in the banking industry that may increase significantly; (13) changes in the interest rate environment that may reduce margins and/or the volumes and values of loans made or held as well as the value of other financial assets held; (14) an unforeseen outflow of cash or deposits or an inability to access the capital markets, which could jeopardize ODNB's or NACB's overall liquidity or capitalization; (15) changes in the creditworthiness of customers and the possible impairment of the collectability of loans; (16) insufficiency of ODNB's or NACB's allowance for credit losses due to market conditions, inflation, changing interest rates or other factors; (17) adverse developments in the financial industry generally, responsive measures to mitigate and manage such developments, related supervisory and regulatory actions and costs, and related impacts on customer and client behavior; (18) general economic conditions, either nationally or regionally, that may be less favorable than expected, resulting in, among other things, a deterioration in credit quality and/or a reduced demand for credit or other services; (19) unusual and infrequently occurring events, such as weather-related or natural disasters, geopolitical conflicts, acts of war or terrorism, or public health events; (20) cybersecurity threats or attacks, whether directed at ODNB or NACB or at vendors or other third parties with which ODNB or NACB interact; (21) the implementation of new technologies, and the ability to develop and maintain reliable electronic systems; (22) changes in business conditions; (23) changes in the securities market; and (24) changes in the local economics with regard to ODNB's and NACB's respective market areas.
These factors are not necessarily all of the factors that could cause ODNB's, NACB's or the combined company's actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm ODNB's, NACB's or the combined company's results. Additional factors that could cause results to differ materially from those described above may be found in the Registration Statement on Form S-4 that ODNB will file with the Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors." The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on ODNB, NACB or each of their respective businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. ODNB and NACB urge you to consider all of these risks, uncertainties and other factors carefully in evaluating all such forward-looking statements made by ODNB and NACB. Forward-looking statements speak only as of the date they are made and ODNB and/or NACB undertake no obligation to update or clarify forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.
Important Additional Information and Where to Find It
In connection with the proposed transaction, ODNB intends to file with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the shares of ODNB common stock to be issued in connection with the proposed transaction. The Registration Statement will include a joint proxy statement of ODNB and NACB, which also constitutes a prospectus of ODNB (the "Joint Proxy Statement/Prospectus") that will be sent to shareholders of ODNB and shareholders of NACB seeking certain approvals related to the proposed transaction. Each of ODNB and NACB may file with the SEC other relevant documents concerning the proposed transaction.
INVESTORS AND SHAREHOLDERS OF ODNB AND NACB AND THEIR RESPECTIVE AFFILIATES ARE URGED TO READ, WHEN AVAILABLE, THE REGISTRATION STATEMENT AND JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ODNB, NACB AND THE PROPOSED TRANSACTION. Free copies of the Registration Statement and Joint Proxy Statement/Prospectus, as well as other filings containing information about ODNB and NACB, may be obtained after their filing at the SEC's website (http://www.sec.gov). In addition, free copies of the Registration Statement and Joint Proxy Statement/Prospectus, when available, also may be obtained by directing a request by email or mail to ODNB at [email protected] or, 8607 Westwood Center Drive, Suite 400, Tysons Corner, VA 22182, Attention: Investor Relations. These documents also may be obtained by directing a request to NACB at 316 Pennsylvania Avenue, SE, Suite 402, Washington, DC 20003, by telephone at 202-851-4483, or by accessing NACB's website at https://www.nationalcapitalbank.bank under "About Us - Investor Relations". The information on ODNB's and NACB's websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
This communication does not constitute an offer to sell or the solicitation of an offer to buy securities of ODNB or NACB or a solicitation of any vote or approval. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, and no offer to sell or solicitation of an offer to buy shall be made in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Participants in the Solicitation
ODNB, NACB and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from the shareholders of ODNB and shareholders of NACB in connection with the proposed transaction. Information about the interests of the directors and executive officers of ODNB and NACB and other persons who may be deemed to be participants in the solicitation of shareholders of ODNB and shareholders of NACB in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Joint Proxy Statement/Prospectus related to the proposed transaction, which will be filed with the SEC. Free copies of this document, when available, may be obtained as described in the preceding paragraph.
June 15, 2026 07:00 ET | Source: Axsome Therapeutics, Inc.
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data on AXS-12 and solriamfetol at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 14-17, 2026, in Baltimore, Maryland.
Details of the presentations are as follows:
Title: Cognitive and Functional Outcomes from the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with Cataplexy
Presentation Date and Time: Monday, June 15, 10:00 - 11:45 a.m. ET
Lead Author: Bruce Corser MD, FAASM, Medical Director of Intrepid Research, Cincinnati, OH
Poster Presentation Session: P-16
Poster Number: 375 Title: Solriamfetol for Excessive Daytime Sleepiness in Narcolepsy and OSA: Post-hoc Multi-dimensional Composite Endpoint Analysis of Phase 3 Trials
Presentation Date and Time: Monday, June 15, 10:00 - 11:45 a.m. ET
Lead Author: Ellen Wertmer, FNP-BC, DBSM, FAASM, Founder of Restorative Sleep Medicine, Charlottesville, VA
Poster Presentation Session: P-16
Poster Number: 386 Title: Symptom Burden and Quality of Life in Patients with Narcolepsy Who Experience Residual Cataplexy: Subgroup Analysis from the CRESCENDO Survey
Presentation Date and Time: Tuesday, June 16, 10:00 - 11:45 a.m. ET
Lead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY
Poster Presentation Session: P-34
Poster Number: 316 About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
